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1 ABSTRACT 
 
Type 1 diabetes (T1D) is one of the most common chronic disorders among children and 
adolescents.  It is perceived as an immune-mediated disease with a subclinical prodromal 
period characterized by the selective loss of insulin-producing beta cells in the pancreatic 
islets in genetically susceptible subjects.  The most important genes contributing to disease 
susceptibility are located in the HLA class II locus on the short arm of chromosome 6.  This 
work aimed at (i) assessing whether it is clinically relevant to classify individuals with signs 
of beta-cell autoimmunity into various stages of preclinical T1D, (ii) evaluating the natural 
history of preclinical diabetes in subjects at risk, (iii) assessing whether HLA-conferred 
disease susceptibility modifies the risk associated with different stages of preclinical T1D, 
and (iv) establishing predictive models for T1D that integrate sociodemographic, genetic, 
immunological and metabolic markers and testing their utility for the prediction of T1D in 
siblings of children affected by T1D. 
 
The population, derived from the "Childhood Diabetes in Finland" Study, comprised more 
than 700 initially unaffected siblings of the index cases with newly diagnosed T1D.  The 
mean age of these siblings at the initial sampling was 9.9 years (range 0.8-19.7 years). The 
first three objectives were addressed based on observation of the siblings for progression to 
overt T1D for an average of 9 years, during which time 35 of them (4.6%) presented with 
clinical disease.  The last objective was approached through observation up to the end of 
2002, i.e. for an average of 15 years.  Twelve additional siblings developed clinical T1D 
during that time, resulting in a total number of 47 progressors (6.7%).  All four diabetes-
associated autoantibodies [islet cell antibodies (ICA), insulin autoantibodies (IAA) and 
antibodies to the 65 kD isoform of glutamic acid decarboxylasze (GADA) and to islet 
antigen 2 (IA-2A)] were analyzed in the initial sample taken from each sibling close to the 
time of diagnosis in the index case.  Eighty-three autoantibody-positive siblings underwent 
an intravenous glucose tolerance test (IVGTT) to assess the first-phase insulin response 
(FPIR).  In addition, a homeostasis model assessment of insulin resistance (HOMA-IR) was 
made based on fasting insulin and blood glucose concentrations.  HLA DR and DQ typing 
was performed in the majority of the subjects. The siblings were divided into four categories 
of preclinical T1D as follows: no prediabetes (no autoantibodies), early prediabetes (one 
autoantibody reactivity), advanced prediabetes (two autoantibodies) and late prediabetes (at 
least three autoantibodies) in classification 1.  Classification 2 included information on 
FPIR and employed the categories no prediabetes (no autoantibodies), early prediabetes 
(one autoantibody reactivity, normal FPIR), advanced prediabetes (two or more 
autoantibodies, normal FPIR) and late prediabetes (at least one autoantibody, reduced 
FPIR).  The data for the analysis of the predictive models included age at first sampling, 
sex, HLA-conferred disease susceptibility, autoantibody positivity and titers, age at 
diagnosis and sex of the index case, the number of children in the family and the number of 
first-degree relatives affected by T1D. In the smaller series comprising the autoantibody-
positive siblings who had undergone an IVGTT, data on the FPIR, glucose elimination rate 
(Kg), HOMA-IR and HOMA-IR/FPIR ratio were also included in the analyses. 
 
The first paper showed that the risk of progression to clinical T1D was clearly associated 
with the stage of prediabetes.  The odds ratio (OR) for progression to T1D was 7.1 in early 
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prediabetes, 32.8 in advanced prediabetes and 209 in late prediabetes according to 
classification 1 and 7.8 in early prediabetes, 38.5 in advanced prediabetes and 1310 in late 
prediabetes based on classification 2.  The time to diagnosis was significantly shorter in 
those with late prediabetes initially than in those with no signs of prediabetes.  According to 
classification 1, 36% of the siblings with signs of prediabetes progressed, 27% remained 
stable and 37% regressed in relation to their initial prediabetic stage during prospective 
observation for an average of 3.6 years, as reported in the second paper. The siblings who 
progressed were younger and had a higher initial number of detectable autoantibodies and 
higher initial autoantibody levels except for IAA, but lower FPIR and Kg , than those who 
regressed.  More than half of the siblings with initial preclinical T1D (56%) progressed, 
34% remained stable and only 10% regressed during the observation period according to 
classification 2.  The third paper showed that there was a higher proportion of siblings with 
late prediabetes (17%) among those with strong HLA-conferred disease susceptibility than 
among those with a weaker genetic predisposition (0.5%), while there was a higher 
proportion of siblings with no signs of prediabetes among the genotypes conferring a 
decreased risk (91% vs 70%). Autoantibodies alone were more sensitive for the prediction 
of future diabetes in siblings than autoantibodies combined with HLA-defined 
susceptibility. Genetic susceptibility played a role in determining whether progression took 
place from the initial prediabetic stage and whether T1D became manifest or not.  The 
fourth paper revealed that young age, an increasing number of detectable diabetes-
associated autoantibodies at initial sampling, an increased number of affected first-degree 
relatives and HLA DR-conferred disease susceptibility predicted progression to T1D.  There 
was a subgroup of 77 autoantibody-positive siblings in whom young age, HLA DR-
conferred susceptibility, an increasing number of autoantibodies, reduced FPIR and 
decreased insulin sensitivity in relation to FPIR were associated with an increased risk of 
progression to T1D.  Age at diagnosis was predicted by age, IA-2 antibody levels and 
number of autoantibodies at initial sampling (R2=0.76; P<0.001).  First-phase insulin 
response and HLA DR-conferred susceptibility were additional predictors of age at 
diagnosis in a smaller cohort of autoantibody-positive subjects. 
 
The above observations imply that it is feasible to grade siblings of children with newly 
diagnosed T1D into categories with significant differences in the subsequent risk of overt 
T1D and in time to diagnosis. Almost half of the siblings with signs of prediabetes at the 
time of diagnosis of the index case progressed further in their preclinical disease process 
during the period of prospective observation.  Advanced and late prediabetes seem to 
represent a point of no return, as regression from such stages is extremely rare. HLA-
conferred diabetes susceptibility has an impact on both the initiation and progression of the 
autoimmune process leading to clinical diabetes in siblings of affected children. Information 
on autoantibody status and levels, HLA-conferred disease susceptibility and insulin 
secretion and sensitivity seems to be useful in addition to age and the family history of T1D 
when assessing the risk of progression to T1D and time to diagnosis in siblings of children 
with newly diagnosed T1D. 
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 ABBREVIATIONS 
 
APC = antigen-presenting cell 
ATP = adenosine triphosphate 
BB = biobreeding 
BSA = bovine serum albumin 
BLG = β-lactoglobulin 
CI = confidence interval 
CF-ICA  = complement-fixing islet cell antibodies 
CNS = central nervous system 
CRS = congenital rubella syndrome 
CTLA4 = cytotoxic T-lymphocyte antigen 4 
DAISY = Diabetes Autoimmunity Study in the Young 
DIPP = Type 1 Diabetes Prediction and Prevention Project 
DiMe = Childhood Diabetes in Finland Study 
DPT-1 = Diabetes Prevention Trial – Type 1 Diabetes 
DTH = delayed-type hypersensitivity 
EBV = Epstein-Barr virus 
ENDIT = European Nicotinamide Diabetes Intervention Trial 
EV = enteroviruses  
HIV = human immuno-deficiency virus 
IgG = immunoglobulin G 
FasL = the specific ligand for Fas in vivo 
FPIR = first-phase insulin response 
GADA = antibodies to the 65 kD isoform of glutamic acid decarboxylase 
GLUT2,4 = glucose transporter proteins 
HLA = human leukocyte antigen 
HOMA-IR = homeostasis model assessment of insulin resistance 
IA-2 = islet antigen 2 
IA-2A = antibodies to the IA-2 protein 
IAA = insulin autoantibodies 
ICA = islet cell antibodies 
ICAM-1 = intercellular adhesion molecule 1 
T1D = type 1 diabetes 
IFN-γ = interferon γ 
Ig = immunoglobulin 
IL-2 = interleukin 2 
IRS = insulin receptor substrate 
IVGTT = intravenous glucose tolerance test 
JDF = Juvenile Diabetes Foundation 
JDFU = Juvenile Diabetes Foundation units 
Kg = glucose disappearance rate 
MHC = major histocompatibility complex 
MMR = mumps-measles-rubella 
NOD = non-obese diabetic 
 5
OGTT = oral glucose tolerance test 
OR = odds ratio 
PAA = proinsulin autoantibodies 
PI3K  = phosphatidylinositol 3-kinase 
PRI = prognostic risk index receiver-operating characteristics (analysis) 
ROC = receiver-operating characteristics (analysis) 
RU = relative units 
SD = standard deviation 
SEM = standard error of mean 
SUMO4 = small ubiquitin-like modifier 4 
TBST = Tris-buffered saline with Tween 20 
T1D  = type 1 diabetes 
TRAIL = TNF-related apoptosis-inducing ligand 
TRIGR = Trial to Reduce T1D in the Genetically at Risk 
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2 INTRODUCTION 
 
Under normal physiological conditions, the entry of glucose into beta cells triggers the 
secretion of insulin, which is carried in the blood to the peripheral tissues, where it binds to 
insulin receptors, resulting in the uptake of glucose by cells and its metabolism into energy 
or storage as glycogen. This mechanism is described in Figure 1 (1). Type 1 diabetes (T1D) 
is a chronic disease, mainly affecting children and adolescents, that is characterized by 
hyperglycemia and ketosis resulting from a lack of the physiological insulin secretion 
described above, due to the destruction of beta cells in the pancreatic islets of Langerhans. 
When clinical symptoms of hyperglycemia caused by T1D (polydipsia, polyuria, weight 
loss and fatigue) appear, it is estimated that over 80-90% of the beta cells have already been 
destroyed. Once beta-cell damage has progressed to the clinical manifestation of T1D, the 
affected subjects require life-long therapy based on subcutaneous injections of insulin. The 
other, more common form of diabetes is type 2, which is classically a disease of adults and 
the elderly. It usually develops slowly and is associated with obesity and hypertension, and 
it is initially characterized by hyperglycemia and peripheral insulin resistance. Our 
knowledge of the pathogenesis of T1D, and especially of the preclinical period, has 
increased substantially during the last 30 years, and it is now perceived as an immune-
mediated disease with a long preclinical period characterized by gradual beta-cell loss. In 
addition to cell-mediated autoimmunity, islet cell antibodies (ICA), insulin autoantibodies 
(IAA), antibodies to glutamic acid decarboxylase antibodies (GADA) and to the protein 
tyrosine phosphatase-related islet antigen 2 molecule (IA2-A), and several other antibodies 
are associated with progression to clinical T1D. Increasing knowledge and intensive 
research into the pathogenesis of T1D have raised hopes of finding an effective treatment 
for halting progressive beta-cell damage in individuals en route to overt disease.   
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Figure 1.   Insulin release and action.  
 
Glucose enters beta cells via the glucose transporter (GLUT2) proteins and ATP is 
generated by glycolysis. This results in closure of the ATP-sensitive K+ channels, 
depolarization of the plasma membrane, and opening of voltage-dependent Ca2+ channels. 
The influx of Ca2+ leads to the release of insulin, which is carried in the bloodstream to cells 
throughout the body, where it binds to insulin receptors. This results in autophosphorylation 
of insulin receptors and phosphorylation of tyrosines on a variety of cellular proteins, 
including members of the insulin receptor substrate (IRS) family and the Cbl-CAP substrate-
adapter protein complex. The phosphorylated proteins provide docking sites for SH2 
domains of several proteins (e.g. phosphatidylinositol 3-kinase [PI3K], Grb2 and SHP2, and 
Crk) that activate different signaling pathways (dashed lines). This leads to translocation of 
the glucose transporter (GLUT4) and uptake of glucose by the cell, alterations in glucose, 
lipid and protein metabolism and changes in gene expression and cell growth (1). 
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3 REVIEW OF THE LITERATURE 
 
 
3.1 Epidemiology 
 
The incidence of T1D, and especially its considerable variation between various parts of the 
world, have been targets of intense research. Extensive registers and bodies of data have 
allowed us in recent years to view the incidence of T1D worldwide, and it has become 
evident that there is major geographical variation in the overall age-adjusted incidence rates 
of T1D in children under the age of 15 over a 5-year period from 1990 to 1994, ranging 
from 0.1/100,000 per year in Zunyi, China, and Caracas, Venezuela, to 36.8/100,000 per 
year in Sardinia and 36.5/100,000 per year in Finland. This represents a 540-fold variation 
in the incidence among the 100 populations observed worldwide, greater than that observed 
for any other non-communicable chronic disease (2; 3). On the other hand, the previously 
assumed “north-equatorial gradient” in the incidence of T1D does not seem to be as strong 
as previously suspected. Although the populations with very high incidence rates were 
mostly of European origin, populations with a relatively high rates were also found in 
tropical or subtropical regions such as Kuwait (4) and Puerto Rico (5). The worldwide 
variation in the incidence of T1D seems partly to reflect the distribution of various races and 
ethnic groups, implying that interpopulation differences in genetic susceptibility to T1D 
may contribute to the differences. Reports on national variations in disease incidence are 
rare, but clear variations have been reported  in the Nordic countries, the United Kingdom, 
Italy and the United States (6), and there are also nearly 50-fold differences in T1D 
incidence within China, for example. In Italy the highest incidence rate (37/100,000/year) 
was observed in Sardinia, with three to six times lower incidence on the mainland, ranging 
from 5 per 100,000/year in Campania to 11 in Pavia  in the age group 10-14 years (7; 8). A 
similar situation has been reported in Canada, with a relatively high incidence of 35.9/100 
000 in Avallon, Newfoundland but rates ranging from 9.3 to 24.5/ 100 000 elsewhere (2; 3; 
9). 
 
The assumption for many years was that there is a considerable increase in the incidence 
rate throughout childhood, with a classic peak in early puberty (10; 11), occurring 1-2 years 
earlier in girls than in boys, and a subsequent decrease, followed by yet another rise later in 
life (12). The maximal growth spurt, characterized by a typical increase in endogenous 
insulin requirements and a decrease in peripheral insulin sensitivity, has been implicated in 
this pattern. The incidence in Finland, however, is reported to be high and quite stable from 
the age of 3 up to 14 years, and no pubertal peak is detectable any longer (13; 14). The 
highest age-specific risk of T1D in the Baltic region, including Finland, has been observed 
around 11–13 years of age. The highest incidence in males of all populations is recorded in 
the 10–14 year age group, whereas that in females is seen in the 5-9 year age group (14). 
 
Although there is usually a female predominance among patients with autoimmune diseases, 
there is typically a higher incidence of T1D in boys than in girls in high-incidence areas, 
e.g.  among Finnish children (15). Conversely, it was assumed previously that there is a 
female excess in low-incidence areas, but a relatively recent study has indicated that there is 
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no longer a statistically significant male excess in the incidence rate in Finland nor a female 
excess in low-incidence countries (2). There is still a noticably higher male excess in the 
high-incidence area of Sardinia, however, which has been linked to the HLA-DR3 allele. 
The linkage between the Xp chromosome and the HLA-DR3 allele has led to a suspicion 
that a gene located on the X-chromosome may play a role in the pathogenesis of T1D (8).  
Most studies indicate that the male excess becomes more apparent among patients 
diagnosed after puberty than in those diagnosed before or during puberty (16; 17). 
 
The issue of a temporal increase in the incidence rate in industrialized countries has been a 
subject of ample debate, and numerous conflicting results have been reported. There is, 
however, evidence of a definite linear increase in T1D among children less than 15 years of 
age in most European countries, especially in Northern and Central Europe, and also in the 
Western Pacific (3; 18-20). This worldwide increase seems to be most conspicuous in 
countries with a low initial incidence rate (2; 3; 21; 22). In Finland, the incidence of T1D 
has increased 4.5-fold over the last 50 years, starting from a figure of 12/100,000 in 1953 
and reaching 54/100,000 in 2003 (23). Tuomilehto et al. demonstrated that the incidence 
increased by more than 60% during the 20-year period 1965-1984, which corresponds to an 
annual increase of roughly 2.4% (15). This trend was seen in both sexes and in three age 
groups (0-4, 5-9 and 10-14 years), and is similar to those observed earlier in Sweden (24). 
There was also a noticable increase in the incidence of the disease in Norway throughout the 
period 1956-1982 (19), both in the age group 0-14 years (25) and in those aged 15-29 years 
(26), but recent results indicate that the incidence remained quite stable in all age groups of 
children under the age of 15 years during the years 1989-1998, although significant regional 
variation was observed (27). The incidence of T1D in Sweden shifted to a younger age 
group at diagnosis during a 16-year period, explaining the earlier observation of an increase 
in the incidence of childhood diabetes (24; 28), and other reports have also found a stable 
incidence rate and a noticeable shift towards a younger age at diagnosis. These observations 
support the “spring harvest hypothesis”, which suggests that the rise in childhood T1D may 
reflect increased exposure to isolated initiating factors in early childhood, as one might 
assume that the number of children with a genetic predisposition has remained stable (22).  
A recent comparison between Finland and Russian Karelia showed that there was an almost 
6-fold difference in the incidence rate of T1D among children under the age of 15 over a 10-
year period from 1990-1999, whereas there was no difference in the frequency of HLA risk 
genotypes in the background population (31).  These observations suggest that the 
conspicuous difference in incidence must be due to factors related to standards of living and 
other lifestyle factors.     
 
There are also some indications that, when populations with a low baseline incidence rate 
move to areas with a higher incidence rate, there is a rapid temporal increase in the 
incidence of T1D (32), and vice versa, e.g. T1D incidence rates have been reported to 
decrease among Sardinians living in Northern Italy, where the disease incidence is 1/3 of 
that in Sardinia (33). Another survey, however, indicates that children of Sardinian lineage 
have an increased risk of developing T1D for at least one generation after migration to 
Northern Italy, especially if both parents are from Sardinia (34). Similar trends were 
observed in the initially low-incidence population of Asian origin living in Great Britain. 
These findings further support the idea that genetic and environmental factors together play 
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a crucial role in the development of T1D. Other theories such as the “hygiene hypothesis” 
emphasize the impact of constantly increasing hygiene, especially in industrialized 
countries, which causes reduced stimulation of the immune system by early infections, 
potentially leading to a reprogramming of the immune system, favoring autoimmune 
diseases in some individuals and atopic diseases such as asthma, hay fever and eczema in 
others (35). 
 
There is considerable evidence to support seasonal variation in the incidence of T1D (36-
40). It has been observed that there is a peak in the incidence of new cases in the cold winter 
months, whereas lower incidence rates are more typical of the warm summer months. It also 
seems that children who will develop T1D are more often born in the summer months (41). 
This variation has been interpreted as suggestive of an infectious etiology, especially the 
involvement of viruses (42; 43). Other results, on the other hand, suggest that if a viral 
infection were the cause of beta-cell damage, the behavior of such a pathogen would be 
quite atypical of viruses. Diseases caused by viruses, such as mumps, measles and coxsackie 
B, which have been proposed as triggers of T1D, usually cause short-term epidemics in 
susceptible populations (44), whereas high-incidence countries seem to have a relatively 
stable or steadily rising incidence rate. In addition, the existence of a long prodromal period 
before the diagnosis of T1D implies that seasonal variation in clinical manifestation would 
reflect the role of infections as precipitating factors rather than as initiators or potentiators of 
beta-cell destruction. There have also been reports of variation in seasonality in relation to 
HLA susceptibility markers, as a more conspicuous seasonal variation has been observed  
among subjects carrying the DR4 allele than among those with DR3 (45; 46).  
 
 
3.2 Pathogenesis of T1D 
 
T1D was presumed earlier to be a rapidly developing disease, resembling those caused by 
acute viral infections, but with increasing knowledge as a consequence of extensive research 
in this field, we have learned that clinical symptoms are preceded by a long chronic 
preclinical period of more than 10 years in some cases characterized by progressive beta-
cell destruction, as illustrated in Figure 2 (17; 47). Sadly, the direct cause that triggers the 
disease is still unknown, although dietary factors and viral infections are suspected to be 
involved in addition to genetic predisposition. Hyperglycemia and ketosis, symptoms 
characteristic of T1D, actually emerge late in the disease process, after most of the beta cells 
have already been destroyed, making the preclinical period an extremely fascinating topic of 
research into the disease process. If the mystery of the pathogenesis of T1D were to be 
revealed completely, this would also open up new possibilities, not only for preventive, but 
also for curative measures (17). 
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Figure 2. Gradual progression of beta-cell damage from initiation to clinical diabetes (80-
90% of beta cells destroyed) [modified from the original (17; 47)]. 
 
 
 
 
 
 
 
 
 
 
 
 
 15
3.2.1 Genetics 
 
Genetic factors play an essential role in type 2 diabetes and the disease tends to run in 
families, whereas most cases of T1D are sporadic, as illustrated by the fact that its 
prevalence among first-degree relatives is only approximately 10% at the time of diagnosis . 
Family studies provided the first evidence in favor of a relation between genetic factors and 
T1D susceptibility, proving that the disease was more common among close relatives of 
affected patients than in the general population (49). The prevalence of T1D in fathers of 
diabetic children is reported to be 3.4-4.4% and that in mothers 1.8-2.0% (50-52). One study 
demonstrated that as many as 7.3% of diabetic children have grandparents with T1D (53). 
The disease risk in a sibling of an affected child has been estimated to be 2.5-10%, 
depending on the population (50; 54-56). The latest figures for siblings and the general 
population in Finland show a cumulative incidence of 4.1% for siblings of children with 
type 1 diabetes by the age of 20 and only about 0.5-0.6% in the general population by the 
age of 35 (57; 58). The lifetime risk of T1D in the Finnish population has been estimated to 
be close to 1% (59). Studies in twins have indicated that 70–75% of the T1D risk may be 
related to genetic effects and 25–30% to environmental factors (60). This appears to be a 
considerable overestimate of the role of genetic factors, however, given that genetic disease 
susceptibility can explain a very modest proportion of the manifold increase in the incidence 
rate seen in most developed countries since World War II. An estimated 23 to 50% of 
monozygotic twins of patients with T1D also develop the disease (61; 62). More than half 
of the affected sib pairs have two identical human leukocyte antigen (HLA) haplotypes, 
40% share one haplotype and only 7% have a non-identical HLA haplotype, as compared 
with the expected distribution of 25%, 50% and 25% (63). The risk of developing T1D is 
approximately 12-24% in HLA-identical siblings, 4-8% in haploidentical siblings and less 
than 1% in non-identical siblings (56; 64-66). The most important determinants of genetic 
susceptibility to T1D are located in the major histocompatibility complex (MHC) or the 
HLA gene area on the short arm of chromosome 6. This gene region, also called IDDM1, 
accounts for 35-60% of the familial clustering of T1D (67-69), while the contribution of 
IDDM2, the insulin gene polymorphism on the short arm of chromosome 11, is less than 
10% (67; 70). The insulin gene is a plausible susceptibility locus, since insulin or insulin 
precursors act as autoantigens in T1D. Ueda et al. recently confirmed earlier results reported 
less than 2 years ago that the gene region encoding the cytotoxic T-lymphocyte antigen 4 
(CTLA4 or IDDM12) on the long arm of chromosome 2 comprises polymorphisms 
associated with an increased risk of common autoimmune disorders such as Grave's disease, 
autoimmune thyroiditis and T1D (71; 72). An additional genetic polymorphism 
predisposing subjects to T1D has been identified recently on the short arm of chromosome 
1, in the PTNPN22 gene encoding the lymphoid protein tyrosine phosphatase, a suppressor 
of T-cell activation (73). Guo et al. reported in 2004 that a single nucleotide polymorphism 
(A163G) in a newly identified gene encoding the small ubiquitin-like modifier 4 (SUMO4) 
was associated with T1D (74). This gene is located in the IDDM5 region on the long arm of 
chromosome 6. Additional work has implied that the mutant SUMO4 protein could result in 
stronger stimulated cellular immune responses, which might explain the association with 
T1D. An overview of the type 1 diabetes susceptibility loci is seen in Figure 3a (75). 
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There are three classes of HLA genes, distinguished according to the structure and function 
of their protein products (Figure 3b) (76). The HLA class I region contains three functional, 
classical class I gene loci, HLA-A, HLA-B and HLA-C, which are highly polymorphic and 
are expressed by all nucleated cells. In addition, there are several other functional class I 
loci, including the non-classical class I genes HLA-E, HLA-F and HLA-G, which are less 
polymorphic and have restricted expression. The HLA class I genes encode the heavy α-
chain of the cell-surface class I  molecule, which, along with the light chain comprising β2-
microglobulin, is responsible for presenting antigens to CD8+ T-cells.  
 
The class II HLA genes, also known as immune response genes, HLA-DR, HLA-DQ and 
HLA-DP, are located at the centromeric end of the complex and encode the α and β-chains 
that form heterodimeric cell surface proteins expressed on the surfaces of antigen-presenting 
cells (dendritic cells, macrophages and B lymphocytes). These class II molecules bind 
foreign antigens non-specifically after their processing and present them to CD4+ T-helper 
lymphocytes. The T-cells are both peptide-specific and HLA-restricted, so that they 
recognize the peptide only when it is bound to a certain class II molecule. The class III HLA 
region comprises genes encoding certain complement components (C2, C4 and properdin 
factor Bf), tumor necrosis factors α and β, heat shock proteins and the 21-hydroxylase 
enzyme. The HLA genes are highly polymorphic, which means that each gene has many 
alleles, leading to extensive variation among individuals, and it is this polymorphism that 
determines the specificity of the immune response (77; 78).  
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                  Figure 3a. An overview of type 1 diabetes suceptibility loci (75). 
 
 
 
 
Figure 3b. The HLA region on the human chromosome 6p21 (76) . 
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There is a close association between the class II  HLA-DR3 and DR4 alleles and T1D (65; 
79), while the HLA-DR2 allele seems to be protective (80). HLA-DR3 and/or DR4 are 
found in more than 90% of Caucasian patients affected by T1D, as compared with a 
frequency of 50-65% among non-diabetic subjects (65; 81; 82). DR3/4 heterozygotes seem 
to have a particularly high risk of developing T1D, since 30-50% of patients carry this 
combination but only 1-6% of the background population, whereas the protective DR2 
allele is present in only about 3% of affected subjects but 25-30% of the general population 
(65; 81-84). DR3/4 heterozygous siblings of affected children have also been shown to have 
multiple T1D-associated autoantibodies, a marker of rapid, aggressive beta-cell destruction, 
more frequently than siblings with other genotypes. The predictive value of the HLA-
DR3/DR4 heterozygous genotype alone, without disease-associated antibody markers, has 
been reported to be 12%-19% among siblings (85; 86). HLA-DQB1 genes seem to confer 
the strongest diabetes susceptibility among the HLA family (87; 88). The HLA-DQ 
molecules associated with an increased risk of the disease or protection against it are listed 
in Table 1(89). The effect is modified by certain DQA1 and DRB1 alleles, however,as these 
are all closely coupled and inherited as coherent entities (haplotypes). A HLA-DQB1based 
risk estimate for Finnish children that defines the presence of the HLA-DQB1*02 and 
DQB1*0302 alleles associated with risk and of the protective DQB1*0301, DQB1*0602, 
and DQB1*0603 alleles is presented in Table 2 (89). A simplified HLA-DQ risk estimation 
model for the Finnish population has been presented by Ilonen et al.: high risk 
(DQB1*02/0302), moderate risk (DQB1*0302/x, where x stands for 0302 or a non-defined 
allele), low risk (DQB1*0301/0302, DQB1*02/0301, DQB1*02/x, DQB1*0302/0602–3, 
where x stands for 02 or a non-defined allele), and decreased risk (DQB1*x/x, 
DQB1*0301/x, DQB1*02/0602–3, DQB1*0301/0602–3, where x stands for a non-defined 
allele) . When a large Finnish nuclear family cohort (n=622) was genotyped for DRB1-
DQA1-DQB1, the DRB1*0401-DQB1*0302 haplotype was found to be the most prevalent 
disease susceptibility haplotype. The results are shown in Table 3 (90). The Childhood 
Diabetes in Finland study showed a prevalence of 35% for at least one autoantibody and a 
frequency of 29% for two or more autoantibodies by the age of 6 years in siblings with the 
high risk HLA-DQB1*02/*0302 genotype (91). A surprising finding in a recent study that 
included three European populations showed that the highest risk in Finland was conferred 
by the DQB1*02/*0304 genotype and that the *0304/*0604 genotype was present only in 
affected cases, although at a low frequency, whereas consistent with previous results, the 
highest disease risk among the DQB1 genotypes in the Hungarian and Greek populations 
was conferred by the *02/*0302 genotype (92). 
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Haplotypes encoding risk-associated molecules  
 
DQA1*0301-DQB1*0302   DR4-DQ8 
DQA1*0501-DQB1*0201   DR3-DQ2 
DQA1*0301-DQB1*0201  DR4-DQ2 (Mediterranean),  
DR7-DQ2 (Black),  
DR3-DQ2/DR4-DQ8 
 
Haplotypes encoding protective molecules 
 
DQA1*0101-DQB1*0602   DR15(2)-DQ6 
DQA1*0501-DQB1*0301   DR5-DQ7 
DQA1*0301-DQB1*0301   DR4-DQ7 
 
 
  
 
Table 1. HLA-DQ molecules associated with increased risk of type 1 diabetes or protection 
against it [modified from the original (89)].
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DQB1*Genotype Children with T1D Newborn infants 
  
 n  %  n  % OR 
 
02/0302 161  (28.8) 303  (2.9)  13.63  
0302  191  (34.1) 1039  (9.9)  4.73  
0302/0603  17  (3.0) 213  (2.0)  1.52  
0301/0302  23  (4.1) 293  (2.8) 1.50  
02  102  (18.2)  1384  (13.1)  1.47 
02/0301  9  (1.6)  321  (3.0)  0.52  
302/0602  6  (1.1)  324  (3.1)  0.34  
Others  27  (4.8)  1704  (16.2)  0.26  
02/0603  4  (0.7)  273  (2.6) 0.27 
0301  10  (1.8)  1049  (10.0)  0.16 
02/0602  2  (0.4) 406  (3.9) 0.09  
0301/0603  1  (0.2)  198  (1.9) 0.09 
0602  4  (0.7)  1421  (13.5) 0.05 
0602 or 0603  3  (0.5)  1264  (12.0) 0.04 
0301/0602  0  (0.0)  349  (3.3) 0.00  
 
Total: 560  10541 
 
 
  
Table 2. HLA-DQB1 genotypes in Finnish children with type 1 diabetes and healthy 
newborn infants [modified from the original (89)]. (OR = Odds ratio) 
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HLA DRB1-DQA1-DQB1 Patients   Controls (AFBAC) 
haplotypes n  %  n  %  Odds ratio (95%CI)  p-value 
 
DRB1*0405-DQB1*0302  5  (0.4) 0    - 11.04  (1.33–91.87) 0.03 
DRB1*0401-DQB1*0302  351 (28.2) 81  (6.5)  5.64  (4.37–7.29)  <10-6 
DRB1*04-DQA1*03-DQB1*0304  10  (0.8)  2  (0.2)  5.03  (1.40–18.08)  0.02 
(DR3)-DQA1*05-DQB1*02  273 (21.9)  95  (7.6)  3.40  (2.65–4.36)  <10-6 
DRB1*0404-DQB1*0302  118  (9.5)  41  (3.3)  3.07  (2.14–4.41)  <10-6 
DRB1*0402-DQB1*0302  1  (0.1)  0    - 3.00  (0.27–33.16)     
(DR13)-DQB1*0604  49  (3.9)  42  (3.4) 1.17  (0.77–1.78) 
(DR9)-DQA1*03-DQB1*0303  55  (4.4)  52  (4.2)  1.06  (0.72–1.56) 
DRB1*04-DQA1*03-DQB1*0301  29  (2.3)  31  (2.5)  0.93  (0.56–1.55) 
(DR7)-DQA1*02-DQB1*02  44  (3.5)  51  (4.1)  0.86  (0.57–1.29) 
(DR8)-DQB1*04  98  (7.9)  125  (10.0)  0.77  (0.58–1.01) 
(DR1)-DQB1*0501  131  (10.5)  225  (18.1) 0.53  (0.42–0.67) <10-6 
(DR16)-DQB1*0502  5  (0.4)  11  (0.9)  0.45  (0.17–1.21) 
(DR4)-DQA1*03-DQB1*02  0    - 1  (0.1)  0.33  (0.03–3.68) 
(DR11/12/13)-DQA1*05-DQB1*0301 34 (2.7) 114  (9.2)  0.28  (0.19–0.41) <10-6 
(DR13)-DQB1*0603  22  (1.8)  109  (8.8)  0.19  (0.12–0.30)  <10-6 
DRB1*0403-DQB1*0302  1  (0.1)  7  (0.6)  0.14  (0.03–0.67)  0.03 
(DR15)-DQB1*0602  17  (1.4)  200  (16.1)  0.07  (0.04–0.12)  <10-6 
(DR14)-DQB1*0503  1  (0.1)  26  (2.1)  0.04  (0.01–0.16)  2x10-7 
(DR7)-DQA1*02-DQB1*0303  0    - 31  (2.5)  0.02  (0.00–0.11)  <10-8 
 
 
 
 
Table 3. Distribution of HLA DRB1-DQA1-DQB1 haplotypes in 622 Finnish children with type 1 diabetes and in affected family-
based artificial controls (AFBAC) [modified from the original (90)].
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3.2.2 Autoantigens and autoantibodies in T1D 
 
The frequency of autoantibodies in the general population is low, e.g. ICA, IAA, and 
GADA are detected in only about 0.5-4% of non-diabetic children (93; 94). ICA have been 
shown to be present in 0.5-4% of non-diabetic subjects, in 3-8.1% of unaffected relatives of 
patients with T1D and in as many as 70-90% of patients with recent-onset T1D (95-100). 
About 4% of Finnish schoolchildren tested positive for at least one diabetes-associated 
autoantibody (59), whereas 13.8% of children with HLA-conferred susceptibility to T1D 
recruited from the general Finnish population had one or more autoantibodies in at least one 
sample by the age of 5 years. By that age 4.4% tested positive for two or more 
autoantibodies in at least one sample. Persistent positivity for two or more autoantibodies 
appears to reflect progressive destructive beta-cell autoimmunity, whereas positivity for a 
single autoantibody may represent harmless non-progressive or even regressive beta-cell 
autoimmunity (101). The presence of autoantibodies in cord blood was not predictive of the 
subsequent development of islet autoimmunity, but was rather the result of maternal 
transmission (102; 103). Autoantibodies are recommended as the first-line screening 
approach in siblings, as the risk of progression to T1D increases with the number of 
autoantibody reactivities detected (104). The addition of genetic markers increased the 
positive predictive values of all the autoantibodies substantially, but resulted in reduced 
sensitivity among the siblings of affected children.  High-risk DQB1 genotypes seem to 
predispose children more strongly to the emergence of each T1D-related autoantibody 
reactivity and multiple autoantibodies than the moderate-risk genotypes (101).  
 
3.2.2.1 Islet cell antibodies 
 
ICA, first detected in patients with T1D more than 30 years ago (105), are antibodies of the 
IgG type, mostly IgG1. These react with antigens located in the cytoplasm of all endocrine 
cells of the pancreatic islets. (106; 107).  Complement fixing ICA (CF-ICA) were described 
by Bottazzo et al. in 1980 as being detectable in the sera of about 50% of patients with 
newly diagnosed T1D, and seemed to correlate more closely with presentation with T1D 
than conventional ICA (108). The predominant opinion at present is that CF-ICA represent 
high-titre ICA (107; 109).  The presence of ICA is detected not only in subjects who 
progress to clinical T1D, but also among non-progressors and in the general population 
(110). In an Australian study, low-titer ICAs (<20 JDFU) were detected in 6.4% of 
schoolchildren and high-titer ICAs (>20JDFU) in 0.9%, the frequency of this marker of islet 
autoimmunity being much higher than the number of children expected to develop diabetes 
(111). Four studies on ICA-positivity in the general population showed that around 0.5%-
25% of ICA-positive children develope T1D (95; 98; 112; 113). The majority of the future 
patients with T1D are to be found in the ICA-positive group, however, where the risk of 
progression to overt diabetes is directly proportional to high ICA titers and young age (114). 
ICA are often present for months or years in individuals who present with T1D later (56), 
and the majority of progressing siblings (73-88%) test positive for ICA at diagnosis (115-
118). The prevalence of ICA often falls considerably after the clinical manifestation of T1D 
(119). The persistence of ICA is presumed to reflect ongoing destructive processes in the 
beta cells (101), so that once all the beta cells in the pancreas have been destroyed, ICA are 
assumed to disappear in the absence of any antigenic stimulation (120). In a Japanese study, 
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children with abrupt-onset T1D had high ICA levels initially, but these decreased rapidly 
after the first year, whereas children with slow-onset T1D were ICA-positive with low titres 
for a relatively long period (121). In some ICA-positive relatives the antibodies have been 
reported to appear and disappear over time, although later surveys have shown this to be 
rare (59). This fluctuation may be a result of inter-assay variability rather than reflecting 
remission of islet cell immunity (122; 123). The distribution of ICA-positivity in first-
degree relatives of patients with T1D in Finland (100) is shown in Table 4. 
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Characteristics Total ICA- ICA+ ICA+ Age, years 
 (>2.5 JDFU) (>18JDFU) mean( + SEM) 
 
 
Female/ 1,415 (56%) 1,317 (57%) 98 (48%) 50 (48%) 
male ratio  /1,107 (44%)  /1,001 (43%)  /106 (24%) a  /55 (52% 20.4(+0.3) 
 
Relation to the 
 proband 
 
Parents  1,012 (40%)  940 (41%)  72 (35%)  32 (30%) 34.8(+0.1) 
Siblings   1,510 (60%)  1,378 (59%)  132 (65%)  73 (70%) b  10.8(+0.2) 
 
Fathers  390 (15%)  361 (16%)  29 (14%)  12 (11%)  35.4(+0.2) 
Mothers  622 (25%)  579 (25%) 43 (21%)  20 (19%)  34.4(+0.2) 
Brothers  717 (28%)  640 (28%)  77 (38%)  43 (41%)  10.5(+0.2) 
Sisters  793 (31%) 738 (32%) 55 (27%)  30 (29%) c  11.0(+0.2) 
 
Total: 2,522 2,318 204 105 
 
 
a p < 0.05. 
b p < 0.05 when compared with parents. 
c p < 0.05 when compared with brothers. 
 
Table 4. ICA-positivity in relatives of children with type 1 diabetes in Finland (SEM = standard error of mean) [modified from the 
original (100)].
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No indications of an association between ICA and HLA class I or class II antigens were 
observed in some earlier reports on patients with T1D (124-126), but other, more recent 
studies have suggested the opposite. The prevalence of ICA was higher in heterozygous 
DR3/DR4 patients than in patients without DR3 or DR4, and high-titer ICA were more 
frequently found together with the HLA DQA1*0301-DQB1*0302 haplotype at the 
diagnosis of T1D in patients younger than 10 years of age (127; 128).  
 
ICA-positive heterozygous DR3/DR4 siblings had a 70% cumulative incidence of 
progression to T1D after an 8-year follow-up, whereas the cumulative incidence in ICA-
negative heterogygotes was only 5% (85). The HLA DQA1*0301-DQB1*0302 haplotype is 
also reported to be associated with high ICA titers in siblings, but these associations were 
only observed in relation to specific genotypes (129). ICA were more frequent and had 
significantly higher titers in siblings of affected children with the high-risk DQB1 genotype 
than in siblings with the low or decreased risk genotypes (130). High levels of ICA seem to 
be related to HLA identity, the DR4 and DQB1*0302 alleles and the susceptible DQB1 
genotypes (131). In another survey the frequency of ICA positivity was higher in those 
siblings who were HLA-identical to the affected sibling (9.9%) than among those who were 
haploidentical (5.3%) or non-identical (2.4 %) (132).  
 
3.2.2.2 Insulin autoantibodies 
 
It was first recognized in 1983 that antibodies against endogenous insulin were detectable in 
subjects with newly diagnosed T1D before treatment with exogenous insulin (133). IAA 
were initially found in 18% of patients with recent-onset T1D, while the current experience 
is that they are present in about 40-50% of such cases (114; 134). IAA are in most cases the 
first autoantibodies to appear in young children with emerging signs of beta-cell 
autoimmunity, implying that insulin may be the primary autoantigen in most cases of 
childhood T1D (115; 135-137). The prevalence of IAA in the general population has been 
reported to range from 0.9% to 3.3% (94; 113; 138; 139) and is reported to be higher among 
siblings of affected children, varying from 1.4 to 6.9% (86; 118; 140-143). There is a 
definite inverse correlation between IAA prevalence and levels and age at the diagnosis of 
T1D, IAA being more frequent and present at higher titers in children developing diabetes 
before the age of 5 years (144). IAA may also correlate with the rate at which beta−cell 
destruction proceeds, the titers being highest in those progressing to diabetes most rapidly 
(145). IAA are quite often detected in non-diabetic subjects with ICA, whereupon their 
simultaneous presence confers a substantially greater risk of progression to T1D than does 
the presence of either antibody alone (134). There is more fluctuation over time in IAA 
levels than in ICA levels, but the reason for this is unknown (123; 146). The presence of 
IAA does not always predict diabetes, but may reflect an inherited propensity to 
autoimmunity. Fluctuations in IAA positivity have been observed, whereas fluctuations in 
other autantibodies are rare (59; 146).  
 
Controversial results have been presented regarding the relation between IAA and HLA 
alleles. IAA were not related to the presence of HLA-DR3 or DR4 in twins (146), and in an 
American study the levels of IAA did not differ with respect to HLA-DR antigens in newly 
diagnosed children with T1D (147). On the other hand, the frequency of IAA was reported 
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to be increased in affected subjects carrying the HLA-DR4 haplotype (131; 148; 149), 
whereas T1D patients with the HLA-DR3 haplotype had very low IAA levels (150). The 
HLA-DR4 allele seems to contribute to the level of anti-insulin autoimmunity, and DR4-
associated diabetes susceptibility is thought to be secondary to this influence, in contrast to 
DR3 susceptibility (148). Like ICA, IAA are also associated with the HLA DQA1*0301-
DQB1*0302 haplotype at the clinical diagnosis of T1D in patients younger than 10 years of 
age (93; 127; 141), and similar associations have been observed in relation to specific 
genotypes in siblings of patients with T1D (129). IAA have also been found to be more 
frequent among siblings of patients with T1D with the high-risk DQB1 genotype 
(DQB1*02/*0302 genotype /DQB1*0302 allele) than in those with low risk genotypes 
(130; 131). DR3/4 hetreozygosity also seems to be linked to high IAA frequencies in 
siblings (131). The role of insulin as an autoantigen in T1D is unequivocal: it is beta-cell 
specific and it is expressed on the surface of the beta cell, but whether this immune response 
is primary or secondary to beta-cell damage remains a open question. Proinsulin, the 
precursor of insulin, has been implicated as a possible autoantigen in T1D, and there has 
been some debate as to whether proinsulin autoantibodies (PAA) may be even more closely 
associated with T1D than IAA (151). No significant difference was observed in the 
prevalence of PAA and IAA among 151 patients with newly diagnosed T1D, or among 114 
age-matched non-diabetic first-degree relatives.  A similar observation was made in a study 
of 179 patients with newly diagnosed diabetes and 1028 schoolchildren, where the reduced 
background prevalence of IAA versus PAA in the school children resulted in an increased 
specificity of IAA and suggested that IAA perform better than PAA in predicting the risk of 
diabetes (152). 
 
3.2.2.3 Glutamic acid decarboxylase antibodies 
 
Autoantibodies to a 64 kD islet-cell protein were detected in patients with newly diagnosed 
T1D in the early 1980’s (153). These antibodies were observed in prediabetic subjects years 
before clinical presentation with T1D, and it was shown later that patients with stiff-man 
syndrome, a rare neurological syndrome affecting the γ-aminobutyric acid nervous system, 
had antibodies recognizing cells in the cerebellum and in the pancreatic islets of Langerhans 
(154). This 64-kD antigen was subsequently identified biochemically as the enzyme 
glutamate decarboxylase (GAD), which catalyzes the formation of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) from glutamine (155). GAD may play a role 
in the inhibition of glucagon and somatostatin secretion in the islets and in the regulation of 
insulin release. Two forms of GAD with different molecular weights exist (GAD67, GAD65), 
but human islets express only the smaller form, GAD65. This is not specific to beta cells, 
however (156). GAD65 antibodies have been detected in 20-90% of cases studied before and 
at the diagnosis of T1D (152; 157), about 5-13% of first-degree relatives and up to 3% in 
the general population (152). The diagnostic sensitivity of GADA for T1D seems to be 
higher in adult subjects than in children (116; 158). Among siblings positive for GADA, 58-
69% subsequently present with clinical T1D (86; 140). There is a significant association 
between ICA and GADA, but it is weaker than that between ICA and IA-2A (116; 157; 
159). GADA levels are higher in postpubertal subjects and females affected by T1D (159; 
160).  Beta-cell destruction seems to be slower in high-risk subjects who are GADA-
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positive than in those testing negative for GADA (161). Humoral immunity to GAD often 
remains elevated in cases where most of the beta cells have been destroyed, even years after 
diagnosis, possibly because GAD65 is also found in other tissues, e.g. in the central nervous 
system (CNS) (117; 159; 162). GADA were more frequent and had significantly higher 
titers among siblings of children with T1D with the high-risk DQB1 genotype (157), while 
their frequency has been reported to be 0.5-4% among non-diabetic siblings with genotypes 
conferring low or decreased risk (130). It has also been suggested that individuals carrying 
the HLA DR3-DQ2 haplotype are more prone to develop GADA (152; 163), although other 
findings suggest that type 1 diabetes susceptibility alleles do not control the development of 
GADA (164). 
 
3.2.2.4 IA-2 and IA-2β antibodies 
 
Antibodies against a 50kD fragment derived from trypsin digestion of the 64kD islet 
protein, as described in 1982, have been observed to react with GADA, whereas 37kD and 
40kD fragments were not reported to interact (153; 165). Patients with T1D were observed 
to have antibodies against all of these proteolytic fragments. Later studies have shown the 
40kD antigen to be identical to the intracellular portion of the islet cell antigen 512 
(ICA512), a transmembrane protein that is a member of the protein tyrosine phosphatase 
(PTP) family (166). ICA512 is now more commonly known as the islet cell antigen 2 (IA-2) 
molecule (167). Notkins et al identified 21 proteins in pancreatic islet cells that are related 
to the PTP family (168), among which IA-2β, also known as phogrin, was shown to be the 
precursor of the 37kD tryptic fragment (169). Humoral autoimmunity to IA-2 and IA-2β is 
mainly directed at the cytoplasmic portions of these proteins. Four antigenic domains have 
been identified in the IA-2 and IA-2β molecules, including autoantibodies specific to the 
juxtamembrane (JM) region, the PTP-like domain of IA-2 and the PTP-like domain of IA-
2β and antibodies that are cross-reactive between the PTP-like domains of IA-2 and IA-
2β (170).  A recent study has compared epitope and isotype-specific IA-2 antibody 
responses and demonstrated that siblings who progressed to clinical diabetes more often had 
juxtamembrane epitope-specific IA-2 antibodiesand less often isotype-specific IgE-IA-2 
antibodies than those who did not progress (170). The non-progressors also had higher 
integrated titers of IgE-IA-2 antibodies. Approximately 50-86% of patients with newly 
diagnosed T1D have antibodies to IA-2, while the prevalence in the general population is 
less than 2% (152; 169; 171-173). IA-2A usually emerge as the last of the autoantibodies, or 
one of the last,  during the preclinical disease process (174; 175), and 58% to 69% of 
siblings positive for IA-2A develop signs of clinical T1D over the next 5-10 years (86; 140). 
The prevalence of IA-2A is similar in both sexes and in children and adolescents, a point on 
which these antibodies differ from GADA, which are associated with female gender and 
older age, and from ICA and IAA, which are associated with young age (114; 145; 159; 
160; 172). A non-diabetic sibling with multiple T1D-associated autoantibodies including 
IA-2A carries an approximately 50-80% risk of developing diabetes within the next 5 years, 
compared with a risk of around 15% in the absence of IA-2A (141; 176). By contrast, IA-
2A positivity in the general population of schoolchildren seems to confer a 6% risk of 
developing signs of overt T1D within 10 years (94). The prevalence of IA-2A is highest in 
those under the age of 5 years, and in patients with HLA DR4, the strongest single allele 
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predisposing subjects to T1D (in contrast to GADA, which are associated with DR3 in 
affected patients), and the HLA haplotype DQA1*0301-DQB1*0302 (104; 116; 152; 177; 
178). ICA titers and IA-2A levels are relatively closely related, suggesting that IA-2 is an 
essential antigen for ICA, while IA-2A and GADA seem to have a weak inverse correlation. 
IA-2A were more frequent among siblings of children with T1D having the high-risk DQB1 
genotype than among those with low risk genotypes (130), and it has been suggested that 
while GADA may be an indicator of general autoimmunity in patients with T1D, IA-2A 
may be a more specific marker of beta-cell destruction (172). The presence of IA-2A is also 
associated with a more rapid progression to clinical T1D in first-degree relatives of affected 
children (104; 174). Like GAD, both IA-2 and IA-2β are also expressed in the CNS as well 
as in the islets.  Though they are obviously major autoantigens in T1D, their functional roles 
have remained undefined (169). IA-2A have a high positive predictive value but a low 
sensitivity compared with ICA, for example, implying that screening programs relying on 
the presence of IA-2A would only identify a small high-risk group while excluding a 
subtantial proportion of the subjects at risk (152). 
 
 
3.2.3 Insulitis and the mechanisms of beta-cell destruction 
 
T1D is the result of T-cell mediated autoimmune destruction of the insulin-producing beta 
cells in the pancreatic islets with the preservation of alpha and delta cells and the cells 
secreting pancreatic polypeptide (1; 179). Two alternative destructive pathways are shown 
in Figure 4. Examinations of the pancreatic tissue from patients who have died shortly after 
being diagnosed with T1D, have revealed that there is pronounced inflammatory infiltration 
by CD8+ and CD4+ cells, B lymphocytes, macrophages and natural killer cells, commonly 
referred to as insulitis (114). The expression of HLA class I molecules on islet cells is 
increased, and class II molecules may be overexpressed on beta cells, macrophages and the 
endothelium. Expression of  intercellular adhesion molecule 1 (ICAM-1) on the vascular 
endothelium has been observed to be increased, a feature favoring the adhesion and 
accumulation of mononuclear cells in the islets (114; 180). Intriguingly, recent studies have 
reported that there is a benign autoimmune response towards the islets in the early neonatal 
phase, and it has been proposed that T1D may develop in those individuals who fail to 
organize a well controlled protective autoimmune response to damaged pancreatic tissue at 
the neonatal stage. Consequently, T1D-prone individuals do not benefit from any 
physiological protective mechanism which counters neonatal beta−cell death by promoting 
processes of apoptotic beta-cell clearance and repair of the damaged islets, and are devoid 
of the postnatal local T-cell activation that subsequently results in the recruitment of islet 
antigen-specific T cells into the pool of peripheral regulatory T cells (181). 
 
Observations that diabetes can be transferred from non-obese diabetic (NOD) mice or 
biobreeding (BB) rats to non-diabetic animals by T lymphocytes support the concept that T 
cells play an important role in the pathogenesis of autoimmune diabetes. The T-cell 
responses seem to be similar in humans, mice and rats. In mice the CD4+ Th1 cells secrete 
mainly interleukin 2 (IL-2) and interferon γ (IFN-γ) and support macrophage activation, 
delayed-type hypersensitivity (DTH) responses and immunoglobulin (Ig) isotype switching 
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to IgG2a. The CD4+ Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and/or IL-13. Several factors, 
including the dose of antigen, the type of antigen presenting cell (APC) and the HLA class 
II haplotype, influence the differentiation of naive CD4+ T cells into specific Th subsets. 
The cytokines themselves are the best characterized factors influencing the differentiation 
into Th subsets. IFN-γ, for example, inhibits the differentiation and effector functions of 
Th2 cells, and IL-12 markedly delays the differentiation of Th1 cells, whereas IL-4, IL-10 
and IL-13 have been reported to inhibit Th1 proliferation (182). Th1 cells provoke the 
disease when transferred to neonatal NOD mice, while Th2 cells only invade the islets, 
without inducing autoimmune diabetes (183). These observations suggest that the balance 
between Th1-associated destructive insulitis and Th2-associated non-destructive peri-
insulitis plays a crucial role in the pathogenesis of autoimmune diabetes. This 
immunoregulatory balance is still unclear, however, and needs to be further investigated. 
The Th1 cells induce a predominantly cell-mediated immune response, while Th2 cells 
direct immunological responses towards humoral immunity. The counterregulatory and 
destructive and non-destructive insulitis mechanisms observed in mice are probably also 
operative in man (182; 184). 
 
In a hypothesis based on the central role of CD8+ T cells as presented in Figure 4A, 
autoantigens that are processed and presented as peptides in a complex with HLA class I 
molecules on the surface of beta cells are recognized by antigen-specific CD8+ cytotoxic T 
lymphocytes (1). These CD8+-cells can kill target cells by causing apoptosis via direct 
contact with surface membrane-bound ligands such as FasL, TNF-related apoptosis-
inducing ligand (TRAIL) and membrane-bound TNFα (185). In addition, target cell killing 
can transpire without cell-to-cell contact, via the secretion of humoral substances such as 
perforin molecules, which are inserted into the membrane of the target cell as tubular 
entities through which the proteases granzyme A and B can pass, activating apoptosis 
nucleases in the cell (1; 185). The Fas-FasL apoptosis pathway seems to play a critical role 
in the destruction of beta cells. Fas is a type 1 transmembrane glycoprotein (cell-surface 
receptor protein) in the TNF/NGF superfamily, while FasL (the specific ligand for Fas in 
vivo) is a type 2 transmembrane glycoprotein in the TNF superfamily(186). In NOD lpr/lpr 
mice, which are deficient in Fas expression because of an incapacitating mutation in the Fas 
gene, spontaneous development of diabetes did not occur. Furthermore, the transfer of a 
particular NOD-derived, islet-reactive CD8+ T-cell clone into young, irradiated NOD 
animals led to diabetes development several days later, but a parallel transfer into NOD 
lpr/lpr recipients did not provoke the disease (187). Another model proposes that the 
immune response may be initiated by a viral protein that shares an amino acid sequence 
(molecular mimicry) with a beta-cell protein (e.g. the non-structural coxsackie virus protein 
2C and GAD), which may result in the appearance of antiviral cytotoxic CD8+ lymphocytes 
that react with self-proteins of the beta cells (188; 189). This promotes the local production 
of cytokines and other inflammatory mediators that induce the expression of adhesion 
molecules in the vascular endothelium of the islets. The activation of endothelial cells 
allows increased adhesion and extravasation of the circulating leukocytes and the 
presentation of beta-cell antigens from the damaged beta cells by infiltrating macrophages 
and lymphocytes (114; 190).  
 
There are some studies that support the “bystander“ hypothesis demonstrated in Figure 4B, 
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in which the destruction of beta cells is due to T-cell-mediated (CD4+) apoptosis, starting 
with the destruction of some beta cells by an exogenous culprit (e.g. a virus, nutrient, or 
chemical of some kind) and the subsequent release of beta-cell proteins  (191; 192). These 
proteins will be taken up by antigen-presenting cells (macrophages) and presented on the 
cell surface by the HLA class II molecules. This together with co-stimulatory molecular 
interactions such as that between B7-1(CD80) or B7-2 (CD86) and the APC and CD28 
receptors on T cells activates the antigen-presenting cells to produce and secrete monokines 
(IL-1, TNFα), and the activated T cells release IFN-γ (1; 193). The magnitude of beta-cell 
damage is dependent on the velocity of the feed-back circuit between the antigen-presenting 
cells and the T-helper lymphocytes, i.e. on the efficiency of antigen 
presentation/recognition, the amount of cytokine production and the capacity of beta-cell 
defense mechanisms. Because of their low superoxide dismutase content, beta cells are 
extremely vulnerable to damage by IL-1. In the course of beta-cell destruction some of the 
cell proteins may be modified by free radicals, strengthening the immune process further 
(187; 192). IL-1 secreted by macrophages and monocytes is cytotoxic to islet beta cells, this 
process being dependent on both the concentration of IL-1 and the metabolic activity of the 
beta cells, because resting cells are resistant to cytotoxic action (192; 194). IFN-γ 
potentiates the effects of IL-1 on beta cells, and experimental data indicate that IL-1-
induced beta-cell destruction is mediated by toxic free radicals such as oxygen (O2-) and 
nitric oxide (NO) produced by macrophages, endothelial cells or beta cells themselves (195; 
196).  Studies on human pancreatic islets have revealed that although combinations of IL-1, 
TNFα and IFN-γ suppress islet insulin release and induce NO generation, human islets are 
more resistant to the effects of NO than rodent islets. It was also observed that even in the 
case of the effects of NO being inhibited, the cytokine effects remained, demonstrating that 
there are also other mediators inflicting damage on beta cells apart from NO, or that 
macrophages or endothelial cells are the main source of NO in human tissue (197). IFN-γ is 
also a potent promoter of beta-cell destruction. It is produced not only by CD4+ Th1 cells, 
but also by CD8+ cells, which are often abundant in islets with insulitis (198). IFN-γ has 
been shown to cause damage to islets regardless of NO (197). It has been claimed that the 
production of IFN-α is more relevant to human islets than IFN-γ, because IFN-α is 
produced by many cells which are infected by viruses, and since histological changes in the 
pancreatic islets occur even before the lymphocytes capable of releasing IFN-γ appear. This 
IFN-α expression induced by viruses is usually a transient phenomenon, but it remains 
unexplained why IFN-α was detected in the islets of a patient who had been diagnosed with 
T1D several months earlier (199).  
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Figure 4. Mechanisms of immune-mediated beta−cell killing.  
 
(A) Direct killing of beta cells. Autoantigens that are processed and presented as peptides in 
a complex with HLA class I molecules on the surface of beta cells are recognized by 
antigen-specific CD8+ cytotoxic T lymphocytes. This results in the excitement of a number 
of co-stimulatory molecules (e.g. FAS/FASL). A cascade of signal transduction events 
ensues, resulting in beta-cell death by apoptosis through one or more effector pathways (e.g. 
FAS/FASL, perforin/granzyme).  
(B) Indirect (bystander) killing of beta cells. Autoantigens that are engulfed, processed and 
presented as peptides in a complex with HLA class II molecules on the surface of APCs 
(e.g. macrophages or dendritic cells) are recognized by antigen-specific CD4+ helper T 
lymphocytes. This excites co-stimulatory molecules (e.g. CD28/CD80) and triggers the 
release of a variety of cytokines (e.g. interferon γ (IFN-γ), tumor necrosis factor α (TNFα), 
and NO from both CD4+ T cells and APCs, resulting in apoptosis of nearby beta cells (1). 
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3.2.4 Environmental factors 
 
It is likely that the T1D disease process is initiated by a non-genetic, probably 
environmental factor or factors operating in a genetically susceptible subject to trigger a 
destructive immune process. These exogenous factors possibly operate over a limited period 
in early childhood to induce the destructive immune process (200). It is even possible that 
the process may already begin in utero. This is followed by a long prodromal period before 
the clinical onset of T1D. The strongest evidence for the role of environmental factors is the 
fact that the concordance rate for T1D in monozygotic twins is only about 30-50% (62; 200; 
201). 
 
3.2.4.1 Viral infections 
 
Viral infections have been implicated in the initiation of T1D for a long time (42). A list of 
potentially pathogenic viruses is shown in Table 5 (202) Acute virus infections can induce a 
transient autoimmune response, and chronic virus infections such as HIV and hepatitis B 
and C can cause persistent autoimmune responses and even severe tissue damage. The 
seasonality of T1D and the increased frequency of viral antibodies in subjects with T1D, the 
isolation of certain viruses from the pancreas of persons who had died soon after the 
diagnosis of T1D and a number of animal studies provide evidence for the association of 
viral infections with T1D (203; 204). There is also evidence of epidemics of T1D in isolated 
areas, further suggesting a link with viral infections (205). 
 
An association between viruses and T1D was first proposed in 1899, when a Dr. Harris 
reported that his patient developed diabetes after a mumps infection (206). There seems to 
be a delayed effect of mumps on the development of T1D, because a lag period of 2-4 years 
has been observed between mumps epidemics and the subsequent rise in T1D incidence 
(204; 207). There is also some documentation of manifestation of T1D after mumps 
vaccinations (207), although other studies have shown no relation between the prevalence of 
diabetes-associated autotoantibodies and the mumps-measles-rubella (MMR) vaccination 
(208). In Finland there was a transient plateau in the steadily rising incidence of T1D after 
MMR vaccinations were introduced in 1983 (209).  
 
Children with the congenital rubella syndrome (CRS) have a high risk of diabetes. An 
autoimmune etiology has been implicated, as islet surface cell antibodies and IAA have 
been detected in 20% of non-diabetic individuals and in 50–80% of patients with diabetes 
after a congenital rubella infection (189). As many as 12–20% of individuals infected with 
rubella in utero will develop diabetes within the next 5–20 years (208; 210-212). In addition 
to the congenital rubella syndrome, isolated cases of T1D have been reported after rubella 
infection in adults (213). CRS has been reported to be associated with the same HLA-DR 
haplotypes as T1D (214; 215), and the rubella virus has been shown to be able to cause 
diabetes in both rabbits and hamsters (210; 216).  A recent report has questioned whether 
CRS-associated diabetes is autoimmune, as was earlier been suspected, since no increased 
frequency of T1D-associated autoantibodies could be observed in a series of subjects with 
confirmed CRS (217).  
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Cytomegalovirus (CMV) has also been implicated in the etiology of T1D (218).  Thirty-five 
percent of patients with newly diagnosed T1D showed serological evidence of a recent 
CMV infection, and the association between ICA and CMV infection can even cause beta-
cell damage, including degranulation (189). Prospective studies have shown that CMV is 
not a major cause of T1D, however (219; 220) 
 
Mammalian genomes contain many retroviral sequences which are transmitted to the next 
generation through DNA. Most of these are non-infectious. The expression of a beta-cell 
specific retroviral antigen p73 in NOD mice is associated with initiation of the pathogenic 
immune process (221). Since it has been observed that IAA and the retroviral antigen p73 
cross-react in patients with T1D and in their relatives, retroviruses have been implicated as 
playing a possible pathogenic role in T1D (203; 222).  These observations have remained 
unconfirmed, however.  
 
Epstein-Barr virus (EBV) has been associated with the clinical manifestation of T1D (189). 
It has been demonstrated that children affected by T1D have lower levels of IgG against an 
EBV capsid protein than the general population, suggesting that patients with T1D have a 
defective immune response to this virus (223). There are EBV sequences that are 
structurally related to the HLA-DQ8 β-chain, and antibodies to this EBV epitope have been 
observed in a number of patients with T1D (224). Although EBV may have precipitated 
T1D in a minority of affected patients, it is probably not a trigger in the majority of patients 
(189). 
 
It is possible that enteroviruses (EV) may play a major role in the pathogenesis of T1D 
(225). Enteroviruses are small, non-enveloped positive-strand RNA viruses belonging to the 
picornavirus family (226). The first reports connecting enterovirus infections with T1D 
were published more than 30 years ago by Gamble and Taylor, showing that coxsackie virus 
B antibodies are more frequent in patients with T1D than in control subjects (227). There is 
a conspicuous connection between epidemics of EV and subsequent rises in the incidence of 
T1D (228; 229). Several studies have demonstrated increased frequencies of enterovirus 
RNA in children with T1D (33%) compared with non-diabetic controls (4%) (226). The 
prospective Diabetes Autoimmunity Study in the Young (DAISY) in the United States and 
the German BABYDIAB study failed to find any association between enteroviruses and 
T1D (230; 231), but the extensive prospective Type 1 Diabetes Prediction and Prevention 
(DIPP) Project in Finland has revealed an unequivocal temporal association between 
enterovirus infections and the appearance of the first diabetes-associated autoantibodies 
(227). An increased frequency of enterovirus RNA has also been observed in the peripheral 
circulation of patients with newly diagnosed T1D (232). Enteroviral IgG and IgM levels 
have been reported to be increased during pregnancy (225) or at delivery (233) in mothers 
whose offspring later progress to T1D diabetes as compared with control women. A few 
studies have suggested that in some cases the diabetic disease process could already have 
been initiated by maternal enterovirus infections during pregnancy (234). Prospective 
studies have shown signs of an excess of enterovirus infections years before clinical 
presentation (225; 235; 236). It is also known that several enterovirus strains are capable of 
damaging human beta cells in vitro (237; 238).  
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Strong  suspicion of association with type 1 diabetes 
 
Enteroviruses 
-Coxsackie A strains (epidemiological investigations) 
-Coxsackie B strains – All six types are associated with autoimmunity, especially 
B4 (extensive epidemiology). Induces diabetes in mice. 
-Echoviruses (epidemiological investigations). 
 
Rubella  
Follows intrauterine infection in offspring. Diabetes may appear after a long time 
period. Positivity for islet cell surface antibodies has been observed. Vaccination 
entails an attenuated risk. 
 
Viruses that might have a modest role in pathogenesis of type 1 diabetes 
 
Cytomegalovirus 
A cross-reactive epitope with GAD 65. 
 
Epstein-Barr virus 
Associated with autoimmune diseases, including diabetes. 
 
Mumps 
Many reports, but the role is still not confirmed. Vaccination entails an attenuated 
risk. 
 
Retrovirus  
Evidence is controversial in humans. 
 
Rotavirus 
Reports of islet autoimmunity in children after rotavirus infection. 
 
 
 
Table 5. Viruses implicated in the pathogenesis of type 1 diabetes [modified from the 
original (202)].  
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3.2.4.2 Dietary factors 
 
Nutritional factors have been suspected of being involved in the development of T1D, but 
research into this issue is limited and the results often contradictory.  
 
Certain proteins, especially cow’s milk proteins, have been reported to induce autoimmune 
diabetes in the BB rat (239; 240). Increased levels of IgA antibodies to cow’s milk and β-
lactoglobulin (BLG) have been observed in children with newly diagnosed T1D (241; 242), 
and higher IgG antibodies to BLG and bovine serum albumin (BSA) have been reported in 
diabetic children (241; 243). An inverse correlation has been observed between the duration 
of breast feeding and the risk of developing T1D (239; 244; 245). A recent double-blinded, 
randomized pilot nutritional intervention trial involving feeding on either casein hydrolysate 
or conventional cow's milk-based formula until the age of 6-8 months demonstrated that the 
cumulative incidence of autoantibodies by the age of 5 years was somewhat smaller in the 
casein hydrolysate group, hinting at a possiblity for manipulating spontaneous beta-cell 
autoimmunity by dietary intervention in infancy (246). Positive correlations have been 
reported between the average consumption of cow’s milk and the incidence of T1D in 
various countries (247), and it has been observed in Finland that a high daily consumption 
of native cow’s milk (≥3 glasses of milk) beyond infancy is associated with an increased 
risk of seroconversion to autoantibody positivity and progression to overt T1D among 
initially unaffected siblings of children with T1D (248). Maternal cow’s milk consumption 
seems to have no effect on the later life of the child, as elimination of cow’s milk from the 
maternal diet during the last trimester of pregnancy had no effect on the emergence of 
diabetes-associated autoantibodies in the offspring in a Swedish study (249). 
 
Streptozocin, which is chemically related to nitrosamines, has been shown to induce 
diabetes in experimental animals (250), and similar compounds may be present in the diet or 
may be produced from nitrites and nitrates in the gastrointestinal tract (251). There is a 
possible association between the risk of developing T1D and the intake of nitrates and 
nitrites, as long-term frequent exposure to nitrosamines is potentially toxic to beta cells 
(239). An association between the intake of nitrates and nitrites and diabetes has also been 
observed in Finland (252).  
 
Many food products that are rich in carbohydrates are also rich in wheat gliadin, which is a 
protein observed to induce autoimmune diabetes in BB rats (239; 253). Alternatively, it is 
also possible that the carbohydrate-rich food induces beta-cell stress, which makes these 
cells more susceptible to damage by various cytokines at least in experimental models (192; 
194; 254). Soy is also a subject of controversy, since there are animal experiments that 
implicate it as being diabetogenic, while others have observed that soy suppresses the 
development of diabetes (255). 
 
The ‘Accelerator Hypothesis’, which aims at explaining the increase in the incidence of 
T1D in childhood, and also the acceleration in its development, Imaintains that children 
who are heavier as toddlers run a higher risk of T1D later in childhood The increase in 
insulin resistance as a consequence of weight gain in children up-regulates metabolic 
activity in the beta cells, and is thereby also likely to increase their immunogenicity (256; 
 36
257). A 10% increment in relative weight relative to controls was associated with a 50 to 
60% increase in the risk of T1D before the age of three in Finnish children and a 20 to 40% 
increase after that age (258). 
 
3.2.4.3 Additional factors 
 
Other exogenous factors have also been inplicated as being associated with T1D. 
Plasmodium falciparum is suspected to have a protective role in relation to T1D, mediated 
by genetic selection. Areas with past high malaria morbidity seem to be associated with a 
lower risk of T1D, and it may also be an indicator of other parasitic infection that could be 
protective against T1D. Vaccinations have also been associated with an increased risk of 
developing T1D (209; 259), although a recent Danish study could not find any evidence of a 
link with childhood vaccinations (217). Vitamin D has also been associated with protection 
from the development of autoimmune diseases in animal models, although further studies 
are needed to investigate its role (260; 261). The link between psychological stress and 
unfavorable diabetes control is widely accepted, and there has been some debate on the role 
of stressful events in the development of T1D. Numerous large, well-controlled surveys 
have failed to find any unequivocal evidence that T1D is caused by stressful life events 
(262). 
 
 
3.3 Prediction of type 1 diabetes 
 
Genetic and immunological markers, and metabolic indicators such as glucose tolerance and 
first-phase insulin response to intravenous glucose, provide information that facilitates the 
identification of individuals at risk of progression to clinical T1D. Predictions are still far 
from accurate at the individual level, but increasing knowledge accumulated over the past 
20 years regarding the natural course of preclinical T1D has gradually improved our 
methods of risk assessment. It is crucial to develop an optimal predictive strategy for the 
identification of potential progressors to T1D in order to enable successful T1D prevention 
as soon as effective preventive modalities have been established. 
 
 
3.3.1 Relatives of patients with T1D 
 
The presence of ICA has formed the basis for predicting T1D in first-degree relatives for a 
long time. ICA positivity in unaffected first-degree relatives of children with T1D is 
associated with a 30–50% cumulative risk of progressing to clinical diabetes within 5–10 
years, and this risk increases with increasing ICA titers, as siblings positive for ICA alone 
have a cumulative risk amounting to 50-60% of progressing to T1D within 10 years (95-97; 
104; 140; 141). IAA alone are not very useful in this respect, but in combination with ICA 
they are more predictive of the disease than ICA alone (97; 134; 263; 264). GADA are 
common in combination with ICA, but rare in their absence (159; 265). It has been claimed 
that GADA do not significantly increase the risk of progression to T1D conferred by ICA 
and IAA in combination (104; 159), however, the combination of GADA with IA-2A seems 
to be as effective as ICA in screening for autoimmunity in children with newly diagnosed 
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diabetes (140; 141; 266-268). High levels of GADA have been associated with a low risk of 
progression to T1D, which is consistent with the assumption that distinct subsets of ICA and 
GADA with variable prognostic significance can be identified (269). It seems, however, that 
as many as 42-55% of GADA-positive first-degree relatives of children with T1D develop 
signs of clinical diabetes within 5-8 years (140; 141). High ICA titers (>80JDFU) have been 
inversely associated with age, and persistently high ICA titers are particularly predictive of 
T1D (104; 142). IA-2A have been reported as being highly specific predictors of the 
development of T1D, as they seem to appear at a relatively late phase of the preclinical 
disease (169; 172; 173). A combination of high-titer IA-2A and IAA has also been found to 
confer a high risk of progression to T1D among first-degree relatives (270), while GADA 
did not increase the risk any further. IA-2A have also been associated with rapidly 
progressive T1D presenting at a young age (104; 116). The DiMe study demonstrated that 
the higher the levels of ICA, IAA and IA-2A, the higher the risk for T1D, whereas GADA 
titers did not add to the risk (140). The presence of multiple autoantibodies is highly 
predictive in family members of affected patients as compared with single antibody 
positivity, the risk of T1D rising from less than 10% when ICA are detected alone to more 
than 80% when at least three antibodies are observed (104; 116; 141; 271). It has also been 
suggested, however, that screening of relatives of patients with T1D for GADA, IA-2A and 
IAA provides sufficient information, so that screening for all four disease-associated 
autoantibodies (ICA,GADA, IA-2A and IAA) is unnecessary, as the detection of two or 
more autoantibodies has been reported to have a positive predictive value exceeding 90% in 
some series (141). Age also seems to be a factor modifying the risk of T1D in ICA-positive 
relatives, with the highest risk found in children below the age of 10 years (97). 
 
The intravenous glucose tolerance test (IVGTT, see Methods) is an efficient method for 
determining the degree of beta-cell dysfunction, and a reduced first-phase insulin response 
(FPIR see, Methods) has been shown to be highly predictive of progression to T1D in ICA-
positive first-degree relatives (272). Prediction of the time to diagnosis by estimating beta-
cell loss on the basis of FPIR does not seem to be feasible, however (273; 274). The 
combination of two positive ICA results and two reduced FPIRs has been shown to be a 
reliable tool for identifying future progressors to T1D among children and adolescents (275-
277), but although the loss of FPIR is associated with a high risk of overt diabetes, this risk 
is considerably modulated by other risk markers such as the levels of ICA and IAA (278). 
The reduction in FPIR is a late phenomenon in the T1D disease process, and accordingly 
there is only a limited time for possible intervention after its observation. A French study 
has shown the sensitivity of two or more low insulin responses to intravenous glucose to be 
60% and the specificity 96% in family members of children with T1D, while the positive 
predictive value was 43% (279). 
 
It is 5-10 times more probable that a monozygotic twin will present with T1D than any 
other type of sibling, although siblings in general have a greater risk of progression than the 
general population (127; 132; 280). In an American study there was a risk of progression to 
clinical T1D of 20% for an initially non-diabetic monozygotic twin within 10 years of 
diagnosis in the index case and 29% within 25 years, while British data provided slightly 
lower frequencies, with a risk of 19% within 10 years of diagnosis in the index case and 
27% within 25 years (281). 
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The risk of HLA-identical siblings developing T1D has been observed to be 10-30% by the 
age of 20-30 years (56; 282; 283), and it has been reported that the DR or DQ genotype in 
the family may confer an even greater risk than the degree of HLA identity (85; 284). 
Though the predictive value of genetic factors alone is relatively low, the combination of 
ICA screening with genetic factors improves the prediction of T1D in first-degree relatives, 
since more than 30% of ICA-positive HLA-identical siblings were observed to progress to 
T1D within 5 years compared with 7% of those who were ICA positive but haploidentical 
or non-identical (132). In France, ICA-positive, DR3/4 heterozygous siblings had a 
cumulative risk of 70% of developing T1D within 8 years (85). By contrast, the 
DQB1*0602 allele is protective in first-degree relatives testing positive for ICA (285), 
although the protective effect is overcome by high antibody levels (142).  
 
 
3.3.2 The general population 
 
As mentioned earlier, close to 90% of all patients with T1D have no family history of the 
disease at diagnosis, and accordingly it is apparent that successful intervention is needed at 
the population level to achieve a substantial reduction in the incidence of T1D (13; 48; 286). 
As our knowledge of risk assessment in first-degree relatives of children with T1D is 
increasing, especially in siblings, the challenge now is to try to identify future diabetic 
patients in the general population.  When assessing the predictive value of ICA positivity 
among children with no familial history of T1D in relation to the risk of progression to 
diabetes within 10 years, it became evident that ICA are only 2-3 times more prevalent in 
siblings than in the general population (287). This makes ICA positivity a quite weak 
marker for future T1D in the general population, since T1D is more than 10 times more 
frequent in siblings than in the background population. Also, the reported proportions of 
initially ICA-positive subjects becoming ICA-negative during follow-up have been 
relatively high in the general population, varying from 14% to 78% in different studies 
(287-291). Another survey has indicated, however, that ICA-positive schoolchildren with 
levels of 10 JDFU or more have a risk of progressing to T1D that is similar to that seen 
among first-degree relatives testing positive for ICA (113). Only a small proportion of 
children in the general population with signs of an immune response to islet cells will 
progress to T1D (287). The following ICA frequencies have been observed in various 
countries: 4.1% in Finland, 3.0% in Sweden, 2.8% in England, 1.5% in France and 1.7% in 
the State of Washington, USA (39; 98; 115; 282; 287), suggesting that there is a correlation 
between the frequency of ICA in the background population and the incidence of T1D. 
There are two studies that have shown a positive association between ICA and the 
frequency of high risk HLA-DQB1 genotypes in the population (39; 280). On the other 
hand, DQB1 alleles conferring decreased disease susceptibility do not provide protection 
from humoral beta-cell autoimmunity, deterioration of beta-cell function or progression to 
overt T1D in initially unaffected schoolchildren (292). The appearance of autoantibodies 
over the first 2 years of life in 1005 children with increased HLA DQB1-conferred 
susceptibility to T1D is illustrated in Figure 5 (17). Early screening for HLA-conferred 
susceptibility to T1D in the general population followed by consecutive screening of the 
genetically susceptible individuals for diabetes-predictive autoantibodies might provide a 
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feasible strategy for the identification of high-risk subjects in the population. This is the 
approach taken in the Finnish DIPP Study (293). In a recent survey of 11,840 
schoolchildren in Germany who were tested for all four diabetes-associated autoantibodies, 
821 (6.9%) children were positive for a single autoantibody, whereas 83 (0.7%) had 
multiple autoantibody specificities. If the primary screening were performed by testing 
GADA/IA-2A/IAA, 94% of probands with single antibodies and all those with multiple 
antibodies would have been identified. The combination of GADA/IA-2A identified 97.6% 
of the probands at risk, GADA/IAA 98.8% and IA-2A/IAA as many as 85.5% (294). In 
another recent study of 4505 healthy schoolchildren, six subjects developed diabetes, all 
from among the 12 individuals with multiple disease-associated autoantibodies, representing 
a positive predictive value of 50% (95% CI 25–75%) and a sensitivity of 100% (58–100%) 
(295). Another study, however, showed that screening for ICA and IAA failed to identify a 
proportion of the genetically susceptible children who subsequently developed islet 
antibodies. Testing for GADA and IA-2A would not have avoided this. Maximizing the 
sensitivity of detecting the risk of type T1D therefore requires repeated screening for islet 
antibodies throughout childhood (296). Assessing the risk of developing T1D by screening 
genetically predisposed cohorts for disease-associated autoantibody markers provides the 
best possible risk estimation for the time being, but it is still far from being a cast-iron 
model. We do not yet know unambiguously at what age screening should be started, exactly 
how children should be screened and how often the screening should be repeated (297). It 
will be necessary in the near future, however, hopefully with a preventive modality 
available, to have a functional risk assessment model available to target the most 
appropriate subjects for intervention.  
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Figure 5. The appearance of beta-cell autoimmunity in the general population in Finland 
during the first 2 years of life in 1005 DIPP children with increased HLA DQB1-conferred 
susceptibility to T1D [modified from the original (17)].    
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3.4 Prevention of type 1 diabetes 
 
Increased understanding of the long prodromal period preceding the clinical symptoms of 
T1D provides a window for trials aimed at preventing or delaying manifestation of the 
clinical disease. There are three types of prevention: primary, secondary and tertiary. The 
main goal of primary prevention is to reduce the incidence of T1D by reducing the risk of 
the disease through the identification and modification of environmental factors that 
mediate beta-cell destruction. This intervention type focuses on individuals without any 
signs of beta-cell damage.  The purpose of secondary prevention is to reduce the incidence 
by interrupting or slowing down the process of beta-cell destruction. The target for this kind 
of prevention is subjects with signs of ongoing beta-cell damage. Finally, tertiary prevention 
may be initiated after the manifestation of clinical T1D to preserve and facilitate the residual 
beta-cell function or prevent the development of secondary complications (286; 298-300). 
 
Many factors have to be considered when choosing subjects for prevention trials. Sex is an 
important factor, if the intervention modality is based on the use of a drug with potential 
teratogenic effects, in which case women of fertile age should be excluded. Young 
antibody-positive subjects have been observed to have a greater risk of progressing to T1D 
(278), but when studying young cohorts with aggressive beta-cell destruction it should be 
taken into account that weak delaying effects may be missed. All prevention trials in 
progress, with the exception of the DIPP Study, include first-degree relatives, since their 
risk of progression to T1D is more than 10 times higher than that in the general population 
(56). The major clinical target for preventive measures should nevertheless be the general 
population, since almost 90% of patients with newly diagnosed T1D have no affected 
family member. It may be possible to identify subjects from the general population with a 
risk similar to that observed in family members by screening for genetic susceptibility 
followed by monitoring for the appearance of diabetes-predictive autoantibodies (286). 
 
The international Trial to Reduce T1D in the Genetically at Risk (TRIGR) project is a 
double-blind, randomised trial aimed at assessing whether weaning of infants with an 
increased risk of T1D to a highly hydrolyzed formula is capable of reducing the cumulative 
incidence of diabetes-associated autoantibodies and/or clinical T1D by the age of 6 years 
and the cumulative incidence of overt T1D by the age of 10 years.  In the Finnish pilot study 
242 newborn infants who had a first-degree relative with T1D and carried risk-associated 
HLA-DQB1 alleles [HLA-DQB1*0302 and /or *0201 and negative for the protective alleles 
(*0602-03, *0301)] received either casein hydrolysate or conventional cow’s milk-based 
formula up to the age of 6–8 months, after exclusive breastfeeding. The data on the 
emergence of autoantibodies by the age of 4.6 years provided the first evidence ever in man 
that it may be possible to manipulate beta-cell autoimmunity in a safe way, by dietary 
intervention in infancy.  Based on these encouraging experiences, the trial proper was 
initiated in 2002 to provide a final answer to the question of whether weaning to a highly 
hydrolyzed formula protects infants from the emergence of beta-cell autoimmunity and 
from progression to clinical diabetes.  
 
The idea of using nicotinamide in prevention trials with prediabetic subjects was based on 
the observation that it prevents or reduces the disease incidence in animal models of 
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autoimmune diabetes, and that it prolongs remission and preserves beta-cell function in 
human T1D (301; 302). Nicotinamide could potentially protect the beta cell by inhibiting 
poly(ADP)ribose polymerase (PARP) and by repleting intracellular stores of nicotinamide 
adenine dinucleotide (NAD), which prevents cellular damage. Nicotinamide has also been 
reported to inhibit cytokine-induced NO production in the islets and cytokine-induced HLA 
class II expression on cultured cells. The European Nicotinamide Diabetes Intervention 
Trial (ENDIT) screened more than 40,000 relatives, randomizing 552 to either nicotinamide 
or a placebo.  Unfortunately the 5-year follow-up showed that there was no significant 
difference in the rate of progression to clinical diabetes between the two groups.  
Accordingly the European Nicotinamide Diabetes Intervention Trial (ENDIT) failed to 
confirm any protective effect of nicotinamide on the development of human T1D. 
 
Parenteral or oral insulin treatment is based on the hypothesis that antigen-specific therapy, 
e.g. low-dose insulin treatment, may influence beta-cell specific autoimmunity by activating 
suppressor or regulatory T cells and by shifting the balance from a Th1-mediated immune 
response to a Th2-biased one. Evidence supporting this concept has been obtained from 
animal studies, where oral or parenteral insulin therapy prevented diabetes, reduced the 
severity of insulitis and was associated with an increased Th2 response (303; 304). The 
Schwabing Insulin Prophylaxis Trial was a randomized, controlled pilot study designed to 
examine whether insulin therapy can delay or prevent the clinical manifestation of T1D in 
high-risk first-degree relatives of patients with T1D. The eligible first-degree relatives 
screened ICA-positive and had a reduced IVGTT and a normal OGTT upon inclusion. The 
German data suggested that insulin prophylaxis may delay the onset of overt diabetes in 
high-risk relatives (305). The American Diabetes Prevention Trial - Type 1 Diabetes (DPT-
1) initiated in 1996 included two approaches:  parenteral administration of insulin to first 
and second-degree relatives with a T1D risk of more than 50%, and oral administration of 
insulin to those with a risk of 25-50% . The parenteral and oral insulin did not delay or 
prevent T1D, although a borderline significant protective effect of oral insulin was observed 
in a subset of the oral administration subjects with high initial IAA levels (306; 307). In the 
ongoing intervention part of the Finnish DIPP study, genetically susceptible children 
identified from the general population who test positive for at least two T1D-associated 
antibodies in two consecutive samples are being invited to take part in a randomized 
controlled trial evaluating the possible preventive effect of intranasally administered insulin. 
In the DIPP project as a whole more than 90,000 consecutive newborn infants from the 
general population have been screened for HLA-conferred susceptibility to T1D at birth, 
and more than 9,000 children carrying high and moderate-risk HLA-DQB1 genotypes 
continue to be followed up at 3–12 month intervals (308). The DIPP intervention differs 
from previous prevention trials in two aspects:  (i) the target group represents the general 
population; and (ii) the treatment is started as soon as possible after the appearance of at 
least two diabetes-associated autoantibodies. 
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3.5 Prospects for treatment of type 1 diabetes 
 
Normoglycemic control is not easily achieved in patients without any endogenous insulin 
secretion. Accordingly, the only means of keeping such patients in good metabolic control 
without typical organ complications of T1D involves replacement of the pancreatic beta 
cells either with an artificial pancreas or with glucose-responsive insulin-producing tissue 
that is preferentially resistant to any subsequent immune attack.  
 
Islet transplantation aims at physical replacement of the damaged beta cells in the pancreas 
of patients with T1D. This idea was originally introduced in the early 1980’s (309) Islet cell 
transplants can now be performed with greater chances of success than just a few years ago 
(310), but even so, it needs continuous treatment with immunosuppressive drugs to protect 
the islets from recurrent autoimmune responses and allorejection. This may cause problems 
such as mouth ulcers, diarrhea and acne with time and entail longer-term risks including 
malignancy and serious infections, elevation of serum cholesterol and blood pressure, and in 
isolated cases a decline in renal function and acute retinal bleeding (311). 
 
There have also been attempts to construct glucose-sensing, insulin-secreting non-islet cells 
(surrogate beta cells) as replacement tissue. Surrogate cells would optimally remain 
invisible to autoimmune reactivity (312) . Adult stem cell-derived, in vitro-generated islets 
may one day be an alternative to cadaver islets for treating diabetic patients. Embryonic 
stem cells are pluripotent cell lines derived from the inner cell mass of blastocyst-stage 
embryos, and their differentiation in culture may reproduce the characteristics of early 
embryonic development (313). New data suggest that embryonic stem cells may have a 
potential for differentiating into endocrine pancreas cells (314).  
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4 AIMS OF THE RESEARCH 
 
The objectives of this work were:  
 
1. to assess whether it is clinically relevant to classify individuals with signs of beta-cell 
autoimmunity into various stages of preclinical T1D; 
 
2. to assess whether genetic modification of this classification enhances its potential; 
 
3. to evaluate the progression of preclinical T1D in siblings of affected children; and  
 
4. to establish a predictive model for T1D integrating sociodemographic, genetic, 
immunological and metabolic markers and to test its utility for the prediction of T1D in 
siblings of affected children. 
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5 SUBJECTS AND METHODS 
 
 
5.1 Subjects 
 
The population was derived from the nationwide “Childhood Diabetes in Finland“ (DiMe) 
Study, in which children with T1D under the age of 15 years and their families, were invited 
to participate between September 1986 and April 1989. The aim was to evaluate the genetic, 
immunological and environmental factors leading to the development of T1D (315). The 
follow-up was prospective and observation of the siblings was initiated shortly after the 
proband was diagnosed as having T1D. Blood samples were taken at intervals of 3-6 
months during the first 2 years and 6-12 months during the following 2 years. If the sibling 
was found to test negative for ICA and IAA on all occasions over the first 4 years, antibody 
surveillance was discontinued. Siblings positive for ICA and/or IAA on at least one 
occasion over the initial 4 years were subsequently observed at an interval of 12 months or 
less. Such siblings were also invited for sequential intravenous glucose tolerance tests 
(IVGTTs) at an interval of 6-12 months starting from the time when antibodies were 
detected for the first time. All the siblings were observed for progression to T1D up to the 
end of 2002. Observation of the siblings progressing to T1D ended at diagnosis, which was 
based on clinical symptoms and an increased random blood glucose concentration (>10 
mmol/l), elevated fasting glucose concentration (>6.7mmol/l), or  random blood glucose on 
two occasions in the absence of symptoms (316). 
  
The 801 index cases (440 males, 54.9%) in the DiMe study had a mean age of 8.4 years at 
the time of diagnosis (range 0.8-14.9 years), and the mean age of the 83 cases (35 males, 
42.2%) who underwent at least one IVGTT was 9.7 years (range 2.1-19.7 years) at the time 
of the diagnosis of the index case and 11.2 years (range 3.2-20.0 years) at the time of the 
first IVGTT. Siblings testing negative for all autoantibodies were assumed in the subsequent 
classifications to have a normal FPIR. Further data are introduced in Table 6. Autoantibody 
and genetic susceptibility data from the DiMe Study have been published previously (131; 
140; 161; 172; 317).  
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Table 6. Descriptive data. 
 
 
               
 N Males (%) Mean age at initial Data included 
   sampling (years, range) 
 
Substudy I  A 758 351 (46.3%) 9.9 (0.8-19.7) Autoantibody 
Substudy I  B 712 323 (44.5%) 9.9 (0.8-19.7) Autoantibody   
     and metabolic 
 
Substudy II  A 715 325 (45.5%) 9.9 (1.3-20.4)a Autoantibody 
Substudy II B 641 285 (44.5%) 10.0 (1.3-20.4)b Autoantibody
     and metabolic 
      
 
Substudies III,IV A 701 324 (46.2%) 9.9 (0.8-19.7) Autoantibody 
Substudy III B 659 298 (45.2%) 9.9 (0.8-19.7) Autoantibody 
     and metabolic 
 
 
 
Mean age at the final sampling (years, range): 
a 13.2 (1.5-24.1) 
b 13.2 (3.0-24.1) 
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5.2 Methods 
 
 
5.2.1 Islet cell antibodies 
 
The presence of ICA was determined by a standard immunofluorescence assay performed 
on sections of frozen human pancreas from a blood group O donor (105) using fluorescein-
conjugated anti-human IgG (Sigma, St. Louis, MO, USA). End-point dilution titers were 
identified and the results were expressed in Juvenile Diabetes Foundation units (JDFU) 
relative to an international reference standard (318). The detection limit was 2.5 JDFU. The 
sensitivity of the ICA assay was 100% and the specificity 98% in the most relevant 
international standardization round (319). 
 
 
5.2.2 Insulin autoantibodies 
 
IAA were analyzed by a modification (12) of the liquid phase radioimmunoassay described 
by Palmer et al. (133). The samples were treated with acid charcoal to remove insulin prior 
to the assay. 80 µl of serum was incubated for 20h with mono125I(TyrA14)-human insulin 
(Novo Research Institute, Bagsvaerd, Denmark) and the free and bound insulin fractions 
were separated using polyethylene glycol. The results were expressed in nU/ml, where 1 
nU/ml corresponds to a specific binding of 0.01%. The interassay coefficient of variation 
was less than 8%. If the specific insulin binding exceeded 54 nU/ml (representing the 99th 
percentile in 105 non-diabetic subjects), the subject was considered IAA-positive. The 
sensitivity of the IAA assay was 78% and the specificity 100% in the first proficiency 
testing program. 
 
 
5.2.3 Glutamic acid decarboxylase (GAD65) antibodies 
 
An immunoprecipitation radioligand assay was used to detect GADA (161; 320). The 
labeled GAD65 antigen was obtained from recombinant human islet GAD65 cDNA that 
had been transcribed and translated according to the manufacturer’s instructions (Promega, 
Madison, WI, USA) in the presence of [35S]methionine (Amersham, Amersham, Bucks, 
UK). Sera (2 µl) were incubated overnight at +4 0C with approximately 30,000 cpm human 
GAD65 in a total volume of 50 µl Tris-buffered saline with Tween (TBST). To isolate the 
immunocomplexes, 25 µl Protein A-Sepharose® CL-4B (Pharmacia, Uppsala, Sweden) in a 
total volume of 100 µlTBST was added. A scintillation counter was used to count the 
amount of immunocomplexes precipitated. All the samples were analyzed in quadruplicate 
with and without competition from excess amounts of unlabeled recombinant GAD 65 
(1µg/well) produced in an expression system using baby hamster kidney cells and purified 
with Triton X-114 (161). The results were expressed in relative units (RU), representing the 
specific binding as a percentage of that obtained with a positive standard serum. One 
relative GADA unit = 100 ×  [{cpm (unknown sample) - cpm (unknown sample incubated 
with an excess of unlabeled GAD65)} / {cpm(positive standard serum) - cpm(positive 
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standard serum incubated with an excess of unlabeled GAD65)}]. The limit for GADA 
positivity was set at 6.5 RU, which represents the 99th percentile in a series of 372 healthy 
control subjects (321). The disease sensitivity of the GADA assay was 79% and the 
specificity 97% based on the 1995 Multiple Autoantibody Workshop (322) 
 
 
5.2.4 IA-2 antibodies 
 
A radiobinding assay modified from that described by Bonifacio et al. (171) was used to 
analyze IA-2A (172). The recombinant plasmid pSP64poly(A) encoding the intracellular 
portion of the full-length IA-2 protein, including amino acids 605-979 (provided by E. 
Bonifacio, Milan, Italy), was transformed in Esterichia coli JM109 cells and purified by 
standard techniques. The purified plasmid was then transcribed and translated in the TNT 
Coupled Reticulocyte Lysate System (Promega) in the presence of [35S]methionine 
according to the manufacturer’s instructions, to produce the radioactive IA-2 protein. Sera 
(2 µl) were incubated overnight at +4 0C in 96 deep well plates with 10,000 cpm of labeled 
IA-2 protein diluted in 50 µl of 50 mM Tris and 150 mM NaCl (pH 7.4) containing 0.1% 
Tween 20 (TBST). To isolate the immune complexes, 5 µl Protein-A Sepharose®?CL-4B 
(Pharmacia) in a total volume of 50 µl TBST was added on the following day. After 
thorough washing, the radioactivity of the samples was measured with a liquid scintillation 
counter (1450 Microbeta® Trilux, Wallac, Turku Finland) after adding 10 µl of scintillation 
fluid (OptiPhase Supermix, Wallac). Each plate contained a dilution series of a pool of two 
local positive sera diluted in a pool of two local negative sera. A standard curve was 
constructed on each plate using the results of the dilution series (1:2, 1:4, 1:8, 1:16, 1:32, 
1:64, 1:128, 1:512 and the pool of the two negative sera), the dilutions being assigned 
arbitrary values of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39 and 0.1 relative units (RU), 
respectively. A subject was considered IA-2A positive, if the serum antibody levels 
exceeded 0.429 RU, which represents the 99th percentile in 374 healthy Finnish children 
and adolescents. The disease sensitivity of this assay was 62% and the specificity 97% 
based on 140 samples included in the 1995 Multiple Autoantibody Workshop (322). 
 
 
5.2.5 Intravenous glucose tolerance test 
 
The siblings participating in an IVGTT were given a glucose dose of 0.5 g/kg in 3 min (+ 
15 s) after fasting overnight for 10-16 h. Blood samples were taken before the glucose 
infusion and at 1, 3, 6, 10, 20, 30, 40, 50 and 60 min thereafter. Serum insulin 
concentrations were measured radioimmunologically (323) and blood glucose levels by the 
glucose oxidase method (324). The sum of the insulin concentrations at 1 and 3 min was 
defined as the FPIR to glucose. To evaluate the degree of glucose tolerance, the glucose 
disappearance rate (Kg) was assessed and expressed as the percentage decrease in blood 
glucose per minute (%/min). FPIR levels below 45 mU/L, which represents the 3rd 
percentile of FPIR values in healthy control subjects (272), after adjustment for the insulin 
assay used based on an exchange of serum insulin samples between Oulu and Boston, and 
Kg values below 1.30%/min were considered to be abnormal. 
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5.2.6 Homeostasis model assessment of insulin resistance (HOMA-IR) 
 
The HOMA-IR index was calculated to estimate insulin sensitivity. The index was based on 
the formula HOMA-IR = fasting glucose  (mmol/L) x fasting insulin (mU/L) / 22.5, as 
described previously (325; 326).  Insulin resistance was related to insulin secretion by 
calculating the HOMA-IR/FPIR ratio. 
 
 
5.2.7 Genotyping 
 
HLA-A, B, C and DR typing was performed by conventional HLA serology as described by 
Tuomilehto-Wolf et al. (327). The HLA-conferred disease susceptibility was graded in four 
categories: no risk, HLA nonDR3/nonDR4; low risk, HLA DR 3/nonDR4; moderate risk, 
HLA DR4/nonDR3, and high risk, HLA DR3/DR4. 
 
HLA-DQB1 typing was performed by a previously described method based on time-
resolved fluorescence (328). Four sequence-specific oligonucleotide probes were used to 
identify the following DQB1 alleles known to be associated with either susceptibility to or 
protection from T1D in the Finnish population: DQB1*0302, DQB1*02, DQB1*0602 or 
*0603, and DQB1*0301 (317). The genotype was classified into one of four categories: 
high-risk genotype (DQB1*02/0302), moderate-risk genotypes (DQB1*0302/x, where x 
stands for 0302 or a non-defined allele), low-risk genotypes (DQB1*0301/0302, 
DQB1*02/0301, DQB1*02/x, DQB1*0302/0602-3, where x stands for 02 or a non-defined 
allele), and genotypes conferring decreased risk (DQB1*x/x, DQB1*0301/x, 
DQB1*02/0602-3, DQB1*0301/0602-3, where x stands for a non-defined allele). 
 
 
5.2.8 Data handling and statistical analyses 
 
Cross-tabulation and chi-square (x2) statistics were used to analyze distributions and 
frequencies. The parametric one-way analysis of variance was employed when normally 
distributed variables were compared between groups, and the non-parametric Kruskall-
Wallis analysis of variance when analyzing variables with a skewed distribution. The t-test 
was employed for comparisons between two groups in the case of normally distributed 
variables and the Mann-Whitney U-test in the case of variables with skewed distributions. 
Correlation analyses were performed with a non-parametric test (Spearman) due to the 
skewed distribution of the variables tested. The 95% confidence intervals (CI) were 
calculated by the exact method. Cox regression analysis was used to identify factors 
associated with the risk of progression to overt T1D, whereas multiple linear regression 
analysis was employed for the estimation of variables potentially related to the age at 
diagnosis. The data for the analysis of the multivariate model in the case of the total series 
of 701 siblings initially included the following potential predictors: age at first sampling, 
sex, HLA-conferred disease susceptibility (two or four categories), degree of HLA identity 
with the index case, autoantibody positivity and titers (ICA, IAA, GADA and IA-2A), age 
at diagnosis and sex of the index case, number of children in the family, and number of 
first-degree relatives affected by T1D.  In the smaller series comprising 77 autoantibody-
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positive siblings who had undergone an IVGTT, the FPIR, Kg, HOMA-IR and HOMA-
IR/FPIR  ratio (natural logarithm-transformed due to skewed distribution) were also 
included in the analyses.  The Cox regression analyses were performed with the STATA 
statistical software package, version 8.0 (STATA corporation, College Station, TX, USA), 
and the other statistical tests with the SPSS 11 software (SPSS, Inc., Chicago, IL, USA). 
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6 RESULTS 
 
 
6.1 Classifications (I, II, III) 
 
The siblings were classified into four stages of preclinical T1D (no prediabetes, early, 
advanced or late prediabetes) according to two sets of criteria (Table 7). Classification 1 
was based on the number of antibodies detectable in the first sample available.  In most of 
the 758 siblings this sample was obtained within 3 weeks of the diagnosis of T1D in the 
index case. The first group (no prediabetes) included the siblings who tested negative for all 
four antibodies analyzed, ICA, IAA, GADA or IA-2A, the second group (early prediabetes) 
those who had only one of the antibody specificities, the third group (advanced prediabetes) 
those with two antibody specificities, and the fourth group (late prediabetes) those with at 
least three. 
 
Classification 2 was based on a combination of autoantibodies and FPIR. The siblings with 
no antibodies were still placed in the first group (no prediabetes), those with one antibody 
specificity detectable but a normal FPIR comprised the second group (early prediabetes), 
those with two or more antibodies but still with a normal FPIR the third group (advanced 
prediabetes), and those with an abnormal FPIR and at least one antibody specificity the 
fourth group (late prediabetes). Initially antibody-positive siblings with no available FPIR 
were excluded from this classification, leaving 712 siblings in the analysis. 
 
Similar criteria were used when the siblings were classified at the end of the follow-up in 
substudy II. 
 
 
Classification 1. 
 
No prediabetes     AB = 0 
Early prediabetes     AB = 1 
Advanced prediabetes    AB = 2   
Late prediabetes     AB > 3 
 
Classification 2. 
 
No prediabetes     AB = 0, normal FPIR 
Early prediabetes     AB = 1, normal FPIR 
Advanced prediabetes    AB > 2, normal FPIR   
Late prediabetes     AB > 1, decreased FPIR 
 
 
Table 7. Classifications used for risk assessment in siblings of children with type 1 diabetes. 
(AB= autoantibodies, FPIR= first-phase insulin response). 
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6.2 Prediction of of type 1 diabetes in siblings of affected children (I, II, III, IV) 
 
Among the 758 siblings, 35 (4.6%) progressed to clinical T1D during prospective 
observation for an average of 9 years (range 0.02-10.3 years), i.e. by the end of 1997, 
leaving 723 (95.4%) unaffected. Only six sibs in the group with no signs of prediabetes 
initially (0.9%; CI 0.3-2.0%) developed T1D, as compared with three (6.1%; CI 1.3-16.9%) 
in the early prediabetes category, three (23.1%; CI 5.0-53.8%) in the advanced prediabetes 
category and 23 (65.7%; CI 47.8-80.9%) among those with late prediabetes. 
 
Six of the 661 subjects among the 712 with available metabolic data who were classified as 
having no prediabetes (0.9%; CI 0.3-2.0%) progressed to T1D, one of those with early 
prediabetes (6.7%; CI 0.2-32.0%), six (26.1%; CI 10.2-48.4%) with advanced prediabetes 
and 12 (92.3%; CI 64.0-99.8%) with late prediabetes.  Thus there were altogether 25 (3.5%) 
siblings who manifested clinical signs of T1D during the observation period, i.e. by the end 
of 1997.  
 
Among the 712 siblings with available genetic data, the OR for HLA-identical siblings 
presenting with any sign of prediabetes relative to haploidentical or non-identical siblings 
was 1.9 (CI 1.2-3.1)  and that for presenting with late prediabetes was 4.1 (CI 2.0-8.5). The 
HLA-identical siblings with late prediabetes (n=18) had an OR of 775 for clinical diabetes 
by comparison with the haploidentical or non-identical siblings without any signs of 
prediabetes (n=468). Siblings who were heterozygous for DR 3/4 had a five-fold risk (CI 
2.3-10.9) of presenting with any stage of prediabetes and a 25-fold risk (CI 5.3-11.8) of 
presenting with late prediabetes as compared with siblings having the non-DR3/non-DR4 
combination. The DR3/4-heterozygous siblings with late prediabetes initially (n=10) had an 
OR of 1809 for clinical diabetes as compared with those having the non-DR3/non-DR4 
combination and no initial signs of prediabetes (n=201). Similar results were also obtained 
when comparing the DQB1 genotypes, in that siblings with the high risk DQB1 genotype 
had an OR of 90.5 (CI 11.7-703) for presenting with any signs of prediabetes and an OR of 
43.0 (CI 5.3-348) for presenting with late prediabetes as compared with siblings carrying 
genotypes conferring decreased risk. The risk of progression to overt T1D in the siblings 
with the high risk genotype and late prediabetes (n=9) was 1773 relative to the siblings with 
genotypes associated with decreased genetic predisposition and without signs of beta-cell 
autoimmunity (Table 8). 
 
The HLA-identical siblings among the 659 with available genetic and metabolic data had a 
2.2-fold risk (CI 1.2-4.1) of presenting with any signs of prediabetes as compared with the 
haploidentical or non-identical siblings and an OR of 4.4 (CI 1.4-14.1) for presenting with 
late prediabetes. The HLA-identical siblings with late prediabetes (n=7) had a 930-fold risk 
of clinical T1D relative to the haploidentical or non-identical siblings with no signs of 
prediabetes (n=468), and the DR3/4-heterozygous siblings had 7.6-fold risk (CI 2.7-21.1) of 
presenting with any signs of prediabetes and a 23-fold risk (CI 2.7-205) of presenting with 
late prediabetes relative to the non-DR3/non-DR4 combination. The risk of progression to 
T1D was also increased to 804 among the DR3/4-heterozygous siblings with late 
prediabetes (n=5) as compared with those with non-DR3/non-DR4 combinations and no 
initial signs of prediabetes. Similar risk ratios were observed when looking at DQB1 
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genotypes. Siblings carrying the high risk DQ genotype had a 5.7-fold risk (CI 2.3-14.4) of 
presenting with any signs of beta-cell autoimmunity and an 18-fold risk (CI 2.0-169) of 
manifesting late prediabetes relative to those with genotypes conferring decreased risk. The 
risk of progression to overt T1D was 591-fold for siblings with the high-risk genotype and 
late prediabetes relative to those with genotypes conferring decreased risk and with no 
initial signs of prediabetes (Table 9). 
 
The risk of developing T1D in the total series of 701 siblings, followed up to the end of 
2002, was associated with age at first sampling, HLA DR-conferred disease susceptibility, 
number of initially detectable diabetes-associated autoantibodies and number of affected 
family members. Among the 77 autoantibody-positive siblings with metabolic data 
available, the age of the sibling, HLA DR-conferred disease susceptibility, number of 
disease-associated autoantibodies, FPIR and HOMA-R/FPIR ratio proved to be significant 
predictors of progression to T1D. 
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Table 8. Odds ratios (OR) for clinical diabetes in relation to the combination of genetic risk 
(HGR= high genetic risk, DGR= decreased genetic risk) and stage of preclinical diabetes 
based on autoantibodies. 
 
 OR n Type 1   
 (CI)  diabetes 
       
 
HLA IDENTITY: 
 
No prediabetes + DGR 1  468 3  
Early prediabetes +HGR 25.8 (2.3-285) 7 1 
Advanced prediabetes + HGR 155 (25.8-930) 8 4 
Late prediabetes + HGR 775 (122-4162) 18 15 
  
 
HLA DR: 
 
No prediabetes + DGR 1  201 0 
Early prediabetes + HGR -  2 0 
Advanced prediabetes + HGR 100 (4.5-2236) 3 1 
Late prediabetes + HGR 1809 (105-31310) 10 9  
 
 
HLA DQB1: 
 
No prediabetes + DGR 1  197 0 
Early prediabetes + HGR -  2 0 
Advanced prediabetes + HGR 131 (9.2-1873) 5 2 
Late prediabetes + HGR 1773  (102-30609) 9 9 
 
 
HLA IDENTITY: HGR= HLA-identical, DGR= HLA-haploidentical or non-identical 
HLA-DR: HGR= DR 3/4, DGR= non-DR3/non-DR4  
HLA DQB1: HGR= high risk DQB1 genotype, DGR= DQB1 genotypes conferring 
decreased risk 
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Table 9. Odds ratios (OR) for clinical diabetes in relation to the combination of genetic risk 
(HGR= high genetic risk, DGR= decreased genetic risk) and stage of preclinical diabetes 
based on autoantibodies and FPIR. 
 
 OR n Type 1   
 (CI)  Diabetes 
       
 
HLA IDENTITY: 
 
No prediabetes + DGR 1  468 3  
Early prediabetes +HGR 155 (7.8-3099) 2 1 
Advanced prediabetes + HGR 155 (28.9-832) 10 5 
Late prediabetes + HGR 930 (84.2-10274) 7 6 
  
 
HLA-DR: 
 
No prediabetes + DGR 1  201 0 
Early prediabetes + HGR -  1 0 
Advanced prediabetes + HGR 603 (30.1-12077) 4 3 
Late prediabetes + HGR 804 (42.4-15258) 5 4 
  
 
HLA DQB1: 
 
No prediabetes + DGR 1  197 0 
Early prediabetes + HGR -  1 0 
Advanced prediabetes + HGR 985 (53.6-18091) 6 5 
Late prediabetes + HGR 591 (29.5-11837) 4 3 
 
 
 
HLA Identity: HGR= HLA-identical, DGR= HLA-haploidentical or non-identical 
HLA-DR: HGR= DR 3/4, DGR= non-DR3/non-DR4  
HLA DQB1: HGR= high risk DQB1 genotype, DGR= DQB1 genotypes conferring 
decreased risk 
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6.3 Natural course of the prediabetic period (II, III) 
 
Among the 715 siblings with at least two samples available for classification 1, 620 
(86.7%) had no prediabetes, 47 (6.6%) early prediabetes, 13 (1.8%) advanced prediabetes 
and 35 (4.9%) late prediabetes according to the first sample, i.e. a total of 95 (13.3%) 
siblings had signs of prediabetes.  Among the siblings with no initial signs of prediabetes, 
585 (94.4%) remained unaffected throughout the follow-up, while 35 (5.6%) tested 
antibody-positive in the last available sample. Out of these 26 (4.2%) had progressed to 
early prediabetes, one (0.2%) to advanced prediabetes and one (0.2%) to late prediabetes, 
while seven (1.1%) developed signs of clinical diabetes. Among the 47 siblings with initial 
signs of early prediabetes, 32 (68.1%) had reverted to no prediabetes by the end of the 
observation period, nine (19.1%) had remained in the early prediabetes phase, and three 
(6.4%) had progressed to late prediabetes, while three (6.4%) had presented with clinical 
T1D. Correspondingly, one of the 13 siblings initially classified as having advanced 
prediabetes, (7.7%) had seroconverted to antibody negativity by the end of the follow-up, 
seven (53.8%) had retained their stage, one (7.7%) regressed to early prediabetes, and four 
(30.8%) had progressed to clinical T1D, while of the 35 siblings initially having late 
prediabetes, 10 (28.6%) remained at that stage, one (2.9%) regressed to advanced 
prediabetes and 24 (68.6%) progressed to clinical T1D (Fig. 6). Altogether 26 (27.4%; CI 
18.7-37.5%) out of the 95 antibody-positive siblings at the initial sampling remained in the 
same category of prediabetes at the final sampling, while 35 (36.8%; CI 27.2-47.4%) 
experienced regression of their prediabetic stage and 34 (35.8%; CI 26.2-46.3%) progressed 
(Fig. 6). 
 
On the other hand, among the 641 siblings with at least two samples available for 
classification 2, 600 (93.6%) had no prediabetes, only six (0.9%) had early prediabetes, 22 
(3.4%) had advanced prediabetes and 13 (2.0%) had late prediabetes according to the first 
sample. Of the siblings with no signs of prediabetes initially, 584 (97.3%) remained so 
during the follow-up, while 16 (2.5%) seroconverted to antibody positivity, nine (1.5%) 
progressing to early prediabetes, two (0.3%) to advanced prediabetes and five (0.8%) 
developing signs of clinical diabetes. Among the six siblings with early prediabetes initially, 
three (50.0%) regressed to no prediabetes, two (33.3%) remained with early prediabetes and 
one (16.7%) progressed to advanced prediabetes, so that none in this group presented with 
signs of clinical T1D. Of the 22 siblings classified as having advanced prediabetes initially, 
12 (54.5%) remained at that stage, two (9.1%) progressed to late prediabetes and eight 
(36.4%) developed overt diabetes during the follow-up, while one of the 13 siblings with 
late prediabetes initially (7.7%) regressed to advanced prediabetes and the remaining 12 
(92.3%) all progressed to clinical T1D. Altogether 14 (34.1%; CI 20.1-50.6%) out of the 41 
siblings with signs of prediabetes at the initial sampling retained the same stage at the final 
sampling, four (9.8%; CI 2.7-23.1%) had regressed and as many as 23 (56.1%; CI 39.7-
71.5%) had  progressed, a larger proportion than in classification 1 (difference 20.3%; CI 
2.3-38.3%; p = 0.04), while the regression rate was also higher using classification 2 
(difference 27.1%; 13.8-40.4%; p = 0.003) (Fig. 7). 
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According to classification 1 based on autoantibodies, no change occurred in the stage of 
prediabetes in the preclinical period in half of the 38 siblings who progressed to clinical 
disease. All but six of the progressors passed through the stage of late prediabetes.  Among 
these six, four experienced the stage of advanced prediabetes before diagnosis, one had 
early prediabetes, testing positive for IAA only, and one had no signs of prediabetes in her 
first and only sample, taken 6.7 years before she presented with overt T1D.  In the vast 
majority of the progressors who passed through the stage of late prediabetes (27/32; 84%) 
this was the stage that immediately preceded diagnosis, but there were five individuals in 
whom the number of autoantibodies decreased again before diagnosis. One of these 
remained positive for ICA, becoming negative for the other three antibody specificities, 
another became negative for all antibodies except IA-2A, while three initially triple-positive 
subjects became negative for one antibody (one for GADA, one for ICA and one for IAA), 
thus passing through the stage of advanced prediabetes before clinical disease.  
 
Thirteen out of the 25 progressors experienced a change in their stage of prediabetes in the 
preclinical period according to classification 2, the combination of antibodies and FPIR.  
Nineteen siblings passed through the stage of late prediabetes, and in 16 cases this was the 
stage immediately preceding the diagnosis of clinical T1D. Three progressors had a reduced 
FPIR initially, but it subsequently increased in the preclinical period and exceeded the third 
percentile, so that they may be said to have regressed from late prediabetes to advanced 
prediabetes. Among the six progressors who did not experience late prediabetes before the 
diagnosis of clinical T1D, four had advanced prediabetes and one early prediabetes, while 
no signs of prediabetes had been observed in one progressor on initial sampling 6.7 years 
before the diagnosis.  No further samples were available for that girl. Only two progressors 
passed through early prediabetes, with a median duration of 3.2 years (range 1.0-5.5 years), 
16 experienced advanced prediabetes, with a duration ranging from 0.5 to 7.7 years (median 
2.7 years), whereas the median duration of late prediabetes was 1.2 years (range 0.2-4.0 
years) in the 19 progressors who went through that stage. There were no significant 
differences in duration between the stages. 
 
Comparison of the 31 siblings who initially tested positive for one or more antibodies and 
subsequently presented with clinical T1D with the 64 antibody-positive siblings who have 
so far remained non-diabetic showed that those who developed overt disease were younger, 
had a higher number of autoantibodies and higher levels of ICA, GADA and IA-2A in their 
first sample and had a lower FPIR in their first IVGTT. There was substantial overlapping 
between the two groups for all the characteristics studied, however.  
 
When assessing whether HLA-conferred disease susceptibility is related to the natural 
course of preclinical T1D, we observed that the higher the genetic risk, the more likely it 
was that a sibling among the 701 with genetic data available would progress from a milder 
stage to a more severe one. This held true for the degree of HLA identity, since about two 
thirds of the HLA-identical siblings progressed in terms of classification 1, whereas less 
than 20% of the HLA haploidentical or non-identical ones did so. About 40% of the siblings 
who were positive for DR3 and/or DR4 progressed, while only 6% of those carrying the 
non-DR3/non-DR4 combination did so. Close to half of the siblings with DQB1 risk 
genotypes progressed in their prediabetic stage, whereas about 10% of those with DQB1 
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genotypes conferring decreased risk progressed. In contrast, a sibling with decreased HLA-
conferred disease susceptibility was more likely to regress or remain stable in terms of 
prediabetic stage. Similar trends were also seen when the siblings were classified according 
to the combination of autoantibodies and FPIR in relation to the degree of HLA identity, the 
DR phenotype or the DQB1 genotype, but the results remained non-significant. 
 
There was a close association between the HLA-conferred genetic risk and the severity of 
preclinical T1D. Among the 659 siblings with available genetic data, 10% of the HLA-
identical cases had late prediabetes initially, whereas only 3% of the haploidentical and non-
identical siblings were at that stage. When using the criteria in classification 2, 4% of the 
HLA-identical siblings had late prediabetes, while the corresponding proportion among the 
HLA haploidentical and non-identical siblings was 1%. Similarly, when looking at the DR 
phenotypes, HLA DR3 and/or DR4 alleles conferred a greater risk of developing late 
preclinical T1D than the non-DR3/non-DR4 phenotype. According to the second set of 
criteria the difference was less obvious, although the HLA DR3 and/or DR4 alleles were 
still associated with an increased frequency of preclinical T1D. The risk of developing late 
prediabetes was also assessed in relation to the DQB1 genotype. When comparing siblings 
having high, moderate, and low risk genotypes with those having DQB1 genotypes 
conferring decreased risk it was again evident that strong genetic susceptibility is associated 
with an increased risk of developing signs of late prediabetes. This was also true when using 
the second set of criteria. 
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First sample Last sample
No (620) 585 No (618)
26
1
1
7
Early (47) 9 Early (36)
32
3
3
Advanced (13) 7 Advanced (9)
1
1
4
Late (35) 10 Late (14)
1
24
Type 1 diabetes (38)  
 
Figure 6. Course of preclinical type 1 diabetes in 715 siblings of affected children over a median follow-up period of 3.6 (0.01-9.8) 
years. Staging based on classification 1. 
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First sample Last sample
No (600) 584 No (587)
9
2
5
Early (6) 2 Early (11)
3
1
Advanced (22) 12 Advanced (16)
2
8
Late (13) 1 Late (2)
12
Type 1 diabetes (25)  
 
Figure 7. Course of preclinical type 1 diabetes in 641 siblings of affected children over a median follow-up period of 3.5 (0.08-9.8) 
years. Staging based on classification 2. 
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6.4 Duration of the prediabetic period (time to diagnosis) (I, II, III) 
 
There were significant differences in the time to diagnosis between the various categories of 
prediabetes among the 25 individuals who presented with clinical signs of T1D. A 
significantly shorter time to diagnosis was observed in the subjects with late prediabetes 
than in those with no signs of prediabetes. The median duration of early prediabetes was 1.3 
years (range 0.1-5.6 years) in the nine siblings who experienced this stage, that of advanced 
prediabetes was 0.7 years (range 0.02-4.2 years) in the 18 subjects who were at this stage at 
some point, and that of late prediabetes 2.7 years (range 0.01-9.0 years) in the 32 siblings 
who passed through this stage. Thus the advanced prediabetes stage was significantly 
shorter in duration than the late prediabetes stage (p = 0.005). 
 
Siblings with late prediabetes according to classification 1 who had the DQB1*0302/x 
genotype had a significantly shorter time to diagnosis (1.2 vs. 4.3 years; p=0.01) than those 
who were heterozygous for DQB1*02/0302, but no other differences in time to diagnosis 
were observed between the siblings with an increased HLA-defined genetic risk and those 
with decreased genetic susceptibility. 
 
 
6.5 Multivariate risk assessment (IV) 
 
Based on the Cox regression model, we calculated an individual prognostic risk index (PRI) 
for each subject and then performed a receiver-operating characteristics (ROC) analysis to 
define a cut-off index leading to the best separation between progressors and non-
progressors. The cut-off index based on the total series proved to be 0.25, resulting in a 
sensitivity of 78.7%, a specificity of 95.7% and a positive predictive value (PPV) of 56.9% 
for T1D. There were altogether 65 out of 701 (9.3%) siblings with a positive prognostic risk 
index, as many as 37 of whom presented with clinical T1D.  Comparison of the siblings 
who did not progress to overt T1D in spite of a PRI exceeding 0.25 with those progressing 
to overt T1D, in order to define possible factors providing protection from disease 
progression, showed that the non-progressors had a lower total number of autoantibodies 
and lower titers of ICA, GADA and IA-2A at initial sampling and were less often HLA-
identical to the index case (Table 10).   
  
The remaining 636 siblings (90.7%) had a PRI below 0.25, and only 10 of them (1.6%) 
developed clinical T1D.  Comparison of the latter with thse siblings who remained 
unaffected, in order to assess factors predisposing these "protected" children to overt T1D, 
showed that the progressors had higher GADA and IA-2A titers and more autoantibodies 
detectable at initial sampling than the siblings who remained unaffected (Table 10).  
  
It also became evident that none of the 636 siblings with a PRI less than 0.25 had more than 
two autoantibodies detectable and 587 (92.3%) had no autoantibodies, whereas 32 out of the 
65 siblings (49.2%) with an index exceeding 0.25 tested positive for more than two 
antibodies. In addition, the siblings with a PRI less than 0.25 were initially significantly 
older [mean age 10.3 (4.4; SD) years vs. 7.1 (4.1) years; P<0.001].  Among those who 
presented with T1D, the siblings with a PRI exceeding 0.25 had a shorter duration of the 
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preclinical period than those with an index less than 0.25 [mean 4.9 (4.0) years vs. 8.8 (3.3) 
years; P=0.007].  The PRI was inversely related to the duration of the prediabetic period 
(rs=-0.40; p=0.006). 
 
 
6.6 Prediction of age at diagnosis (IV) 
 
The age at disease presentation was most effectively predicted with a linear regression 
model including age, IA-2A levels and number of autoantibodies detectable at initial 
sampling soon after the clinical diagnosis of the index case. This model explained 76% of 
the variation in age at diagnosis among the siblings. When comparing the predicted age at 
diagnosis in the siblings with the observed age , 18 (48.6%) of the observed ages among the 
37 progressors were within the confidence interval of the prediction. The youngest (4.9 
years) and oldest (24.8 years) predicted ages were relatively well in line with the youngest 
(1.5 years) and oldest (24.8 years) observed ages (Table 11A).   
 
The second model for the prediction of age at diagnosis, applied to 77 siblings for whom 
metabolic data were available, was based on the age of the sibling, the initial IA-2A titer, 
the risk conferred by the DR-phenotype and the initial FPIR value. This model explained 
83% of the variation in age at diagnosis. When comparing the predicted ages at diagnosis in 
the 25 progressors with the observed ages, all but one of the observed ages were within the 
confidence interval of the estimated age. The sibling with the youngest predicted age at 
diagnosis (4.9 years) had an observed age of 5.5 years, which was close to the youngest 
observed age (5.4 years), while the oldest (22.4 years) predicted age was well in accordance 
with the oldest observed age (24.8 years) (Table 11B).   
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Table 10. Comparison of PRI in progressors and non-progressors, median (range). (PRI= prognostic risk index) 
 
 PRI<0.25 PRI>0.25 
 Progressors Non-progressors Statistics Progressors Non-progressors Statistics 
 (n=10) (n=626) (n=37) (n=28) 
 
Age at first sampling, mean (SD) 7.4 (4.1) 6.6 (4.0) p=0.34 0.7 (3.3) 10.3 (4.4) p=0.67 
 
Number of autoantibodies 3 (0-4) 0 (0-3) p<0.001 1 (0-1) 0 (0-1) p<0.001  
(AAB) at first sampling  
 
ICA, JDF-units 40 (0-640) 0 (0-160) p<0.001 0 (0-5) 0 (0-40) p=0.22 
 
IAA, nU/ml 37 (0-1238) 29.5 (0-103) p=0.17 20.0 (36-206) 19.2 (0-83) p=0.62 
 
GADA, RU 22.2 (0.6-395) 0.7 (0.0-294) p=0.004 5.4 (0.0-154) 0.4 (0.0-288) p<0.001 
 
IA-2A, RU 10.7 (0.1-159) 0.17 (0.09-115) p<0.001 0.2 (0.3-2.1) 0.19 (0.04-3.7) p=0.035 
 
FPIR, mU/ml 55.5 (5.0-137) 70.5 (47.0-140) p=0.059 73.3 (47.5-173) 94.0 (44.0-286) p=0.16 
 
Kg, %/min 1.52 (0.66-2.6) 1.42 (1.2-4.1) p=0.91 1.54 (1.2-1.7) 1.67 (1.11-3.75) p=0.21 
 
HOMA-index 1.64 (0.15-5.7) 1.94 (1.1-3.7) p=0.26 3.0 (0.99-12) 2.01 (0.17-12) p=0.09 
 
HOMA-IR/FPIR ratio 0.03 (0.01-0.11) 0.03 (0.01-0.05) p=0.42 0.05 (0.14-0.16) 0.02 (0.001-0.16) p=0.54 
 
Number of first-degree relatives 1 (1-2) 1 (1-1) p=0.15 1 (1-1) 1 (1-2) p=0.73 
 
HLAidentity   22/15 9/19  p=0.029 3/7 143/483 p=0.59  
(identical/ 
haploidentical and non-identical) 
 
HLA DR 13/21/2/1 a 5/20/1/2 a p=0.38 8/2 b 320/306 b p=0.07 
(DR3,4 and DR4,x/DR3,y and other DR) a(DR3,4/DR4,x/DR3,y/other DR)   b
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Table 11.  Model for the prediction of age at diagnosis in 65 siblings with a PRI exceeding 0.25 
in the total series (A) and 35 siblings in the smaller series of children with metabolic data 
available (B). 
 
 
A.  Age at diagnosis = 5.24 + 1.38 (age at sampling) – 0.039 [IA2A (RU)] - 0.65 (number of 
autoantibodies detected) 
CASE             NUMBER OF  PREDICTED AGE AT              OBSERVED AGE AT 
   AUTOANTIBODIES          DIAGNOSIS (CI, years)  DIAGNOSIS 
703 3 8.46 (5.75-11.17) 3.83 
705 3 4.91 (2.20-7.62) 1.49 
1505 3 18.17 (15.46-20.88) 15.20 
2703 3 20.23 (17.52-22.94) 16.72 
4003 3 21.73 (19.02-24.44) 24.81 
4308 2 7.76 (5.05-10.47) 5.70 
6703 3 11.63 (8.92-14.34) 12.92 
8406 3 6.53 (3.82-9.24) 7.18 
8407 0 9.30 (6,59-12.01) 8.84 
12805 3 8.61 (5.90-11.32) 9.49 
14206 3 13.10 (10.39-15.81) 19.81 
14512 3 14.73 (12.02-17.44) 13.42 
14513 4 13.74 (11.03-16.45) 18.80 
17406 0 9.01 (6.3-11.72) 15.49 
25303 3 13.52 (10.81-16.23) 10.54 
25304 2 7.14 (4.43-9.85) 5.46 
25603 3 20.52 (17.81-23.23) 20.91 
27203 2 9.23 (6.52-11.94) 5.44 
30703 4 15.95 (13.24-18.66) 12.88 
32403 3 15.68 (12.97-18.39) 15.19 
37003 3 8.59 (5.88-11.30) 10.43 
38705 4 13.41 (10.70-16.12) 17.32 
40004 0 9.47 (6.76-12.18) 13.82 
41904 3 6.87 (4.16-9.58) 3.04 
42303 2 24.83 (22.12-27.54) 24.34 
45205 4 9.27 (6.56-11.98) 17.30 
45303 3 10.25 (7.54-12.96) 6.95 
51605 2 7.69 (4.98-10.40) 6.02 
57204 3 8.66 (5.95-11.37) 10.06 
60304 0 12.14 (9.43-14.85) 9.25  
60503 2 18.52 (15.81-21.23) 13.48 
65103 3 12.14 (9.43-14.85) 14.02 
68705 2 15.53 (12.82-18.24) 20.19 
72004 4 7.62 (4.91-10.33) 5.52 
75204 3 10.03 (7.32-12.74) 9.77 
75205 0 7.75 (5.04-10.46) 9.47 
87303 2 22.94 (20.23-25.65) 22.06 
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B.  Age at diagnosis = -2.82 + 1.12 (age at sampling) – 0.021 [IA2A (RU)]  + 0.066 [ FPIR 
(mU/l)]+ 1.97 [DR genotype (0= nonDR3/nonDR4. 1= DR3/nonDR4. 2= DR4/nonDR3. 3= 
DR3/DR4 )]   
 
CASE             NUMBER OF PREDICTED AGE AT       OBSERVED AGE AT 
      AUTOANTIBODIES       DIAGNOSIS (CI. years)           DIAGNOSIS 
1505 3 16.53 (11.99-21.07) 15.20 
2703 3 18.26 (13.72-22.80) 16.72 
4003 3 19.94 (15.40-24.48) 24.81 
6703 3 12.73 (8.19-17.27) 12.92 
8407 0 9.43 (4.89-13.97)  8.84 
14206 3 15.33 (10.79-19.87) 19.81 
14512 3 15.17 (10.63-19.71) 13.42 
14513 4 16.96 (12.42-21.50) 18.80 
17406 0 11.96 (7.42-16.50) 15.49 
25304 2 4.87 (0.33-9.41) 5.46 
25603 3 21.09 (16.55-25.63) 20.91 
27203 2 6.28 (1.74-10.82) 5.44 
30703 4 15.26 (10.72-19.80) 12.88 
32403 3 16.79 (12.25-21.33) 15.19 
37003 3 9.33 (4.79-13.87) 10.43 
38705 4 15.63 (11.09-20.17) 17.32 
45205 4 15.52 (10.98-20.06) 17.30 
45303 3 6.89 (2.35-11.43) 6.95 
51605 2 7.83 (3.29-12.37) 6.02 
57204 3 11.98 (7.44-16.52) 10.06 
65103 3 11.27 (6.73-15.81) 14.02 
68705 2 17.36 (12.82-21.90) 20.19 
72004 4 7.53 (2.99-12.07) 5.52 
75204 3 12.66 (8.12-17.20) 9.77 
87303 2 22.43 (17.89-26.97) 22.06 
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7 DISCUSSION 
 
When a child presents with clinical symptoms of T1D, a chain reaction of events follows. 
The diagnosis is accompanied by anxiety and worries over the lifetime responsibilities 
facing the parents. The situation leads to a number of questions that are typical and repeat 
themselves continuously when the family meets with the doctor caring for their newly 
diagnosed child. One of the most frequent questions asked by families with more than one 
child is: “Will my other children also develop this disease?” Another frequent question is: 
“When would my other child with a high risk of developing T1D present with clinical 
symptoms?”. The ever-increasing incidence in the general population and the possible 
future preventive and treatment modalities have placed a demand on identifying individuals 
at risk and predicting the natural course of their preclinical disease process.  
 
 
7.1 Limitations of the present research 
 
Finland offers unique possibilities for studying T1D, as the incidence rate is the highest in 
the world. The present results are based on a nationwide survey of siblings of children with 
T1D in Finland, providing an opportunity to observe the genetic, immunological and 
clinical characteristics of the disease in a large population. Even a study of this magnitude 
has its limitations, however. Of the total of 767 siblings, only 48 were diagnosed with T1D 
by the end of 2002, which places limitations on the statistical power of the results and on 
their interpretation when assessing factors influencing the development of the disease. 
Genetic data were not available for all the siblings, and the DQ typing in particular did not 
cover the total cohort.  Only siblings testing positive for at least one autoantibody reactivity 
were invited for an IVGTT.  Seventy-eight of the 97 initially antibody-positive siblings 
(80%) underwent an IVGTT, and accordingly metabolic data were available on these 
subjects.  The statistical analyses were performed on the assumption that autoantibody-
negative siblings had a normal FPIR, whereas the antibody-positive siblings with no 
metabolic data available were excluded from the analyses of the role of metabolic markers. 
As this was a nationwide investigation, samples were taken in different hospitals by a large 
number of staff members, and it has to be taken into consideration that this may have 
introduced increased variability into the results despite the use of standard methods. The 
method used for the analysis of IAA in the DiMe study is not as sensitive as the modern 
microassay, and this may have an impact on the assessment of the role of IAA as a risk 
factor. Predictive models will be important tools for the identification of siblings with a high 
T1D risk when curative or preventive modalities become available, but this stage still lies 
beyond the horizon. 
 
 
7.2 Classification of preclinical diabetes and risk of progression to overt type 1 
diabetes  
 
To facilitate and simplify the assessment of the risk of T1D among siblings of affected 
children, the first stage in this research was to test two types of classification for easily 
identifying siblings with a high risk of T1D, and accordingly possible participants in future 
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prevention trials. There were some differences in the risk of progression in relation to the 
stage of prediabetes that depended on the type of classification used. In classification 1, 
based exclusively on the number of antibodies, the risk of developing T1D was 66% in 
those with late prediabetes, while classification 2, according to both antibodies and FPIR, 
resulted in a risk as high as 92% for siblings in this category. Similar, although smaller 
differences were also observed at the earlier stages of preclinical T1D. This illustrates the 
fact that the analysis of FPIR improves the predictive power of the staging strategy, and it is 
therefore highly recommendable to perform an IVGTT in the case of siblings testing 
positive for one or more autoantibodies. FPIR as such nevertheless remains an indirect 
indicator of the residual beta-cell mass, which usually declines towards clinical presentation 
with T1D (104; 276; 278; 329). 
 
 
7.3 Natural history of preclinical diabetes 
 
The observation that regression to no prediabetes from an initial stage of advanced or late 
prediabetes was an extremely rare phenomenon in our series and was seen in only one 
individual with advanced prediabetes initially supports the concept that preclinical diabetes 
can be graded based on the number of autoantibodies.  Altogether, regression of any kind 
was infrequent among siblings with advanced or late prediabetes initially, as such a 
phenomenon was observed in less than 10% of these siblings.  This finding emphasizes that 
advanced and late prediabetes do reflect destructive beta-cell autoimmunity that will most 
likely result eventually in subtotal beta-cell destruction and overt T1D. Within the time 
frame of the present study, close to 60% of the siblings with initially advanced or late 
prediabetes progressed to clinical T1D.  Our data further support the view that early 
prediabetes often represents harmless beta-cell autoimmunity associated with a relatively 
low risk of progression to clinical T1D. This idea is supported by the observation that half 
or more of those with early prediabetes initially had regressed and had no signs of 
prediabetes at the end of the follow-up. This may be partly due to technical factors, 
probably reflected in the higher proportion of false positive samples among those found 
positive for a single antibody reactivity than among those testing positive for two or more 
disease-associated antibodies.   
 
Comparing the two sets of criteria used for grading the prediabetic process, it seems that 
classification 2, based on a combination of antibody status and FPIR, is somewhat more 
predictive, since the proportion of siblings with a progressive process was significantly 
higher and the proportion of those with regression significantly lower. In fact, all but one of 
the 13 siblings with an initially reduced FPIR presented with clinical T1D during the 
prospective observation. One has to bear in mind, however, that there was a difference in 
the number of subjects included, since not all the antibody-positive siblings agreed to 
undergo an IVGTT. Accordingly, classification 2, which was based not only on the number 
of antibodies but also on the FPIR, covered fewer subjects than the staging based 
exclusively on the number of antibodies. 
 
We observed significant differences in the time to clinical diagnosis in relation to the stage 
of preclinical diabetes, with the shortest average duration recorded in the siblings with late 
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prediabetes. It became evident, however, that there was wide variation in this time period 
within the same stage, e.g. among those with late prediabetes it varied from 0.02 to 7.7 
years. This demonstrates that, although there are significant differences in the time to 
diagnosis among siblings at different stages of preclinical diabetes, the variation from 
subject to subject is extensive, making it difficult to predict the time point of diagnosis on 
an individual basis. We also aimed to assess whether there is any HLA-associated genetic 
marker that predicts faster or retarded progression to clinical T1D.  It has prevously been 
reported that the HLA-A24 allele is associated with rapid progression to T1D in ICA-
positive relatives (330).  The DR3/DQB1*02 haplotype has been observed to be associated 
with a slowly progressive prediabetic process (45), but we observed almost no relationship 
between time to diagnosis and the risk genotype. Accordingly, HLA-defined disease 
susceptibility did not provide any clear-cut explanation for the conspicuous inter-individual 
variation in time to diagnosis. When looking only at the siblings with late prediabetes, we 
observed a shorter time to diagnosis among those with the DQB1*0302/x genotype than 
among those who were heterozygous for DQB1*02/0302. This suggests that the 
DQB1*0302 allele is linked to a particularly aggressive autoimmune process. 
 
It was demonstrated in the first paper that the analysis of four T1D-associated 
autoantibodies facilitates the estimation of T1D risk in unaffected siblings. Although the 
classification into stages of preclinical diabetes based on a combination of the number of 
antibodies and FPIR is an effective tool for grading the disease risk in members of the 
families of affected children, it is obvious that it will not be possible to identify all siblings 
who will progress to clinical disease at the time of diagnosis in the first affected child, since 
some will have no signs of preclinical diabetes at that point. In the first survey six (0.9%) 
out of the 661 children with no signs of preclinical diabetes at the time of diagnosis of the 
index case in the family subsequently presented with clinical T1DThe majority of these 
seroconverted to antibody positivity later in the prediabetic process, however.  Staging of 
preclinical T1D may prove an important tool in the near future for the identification of 
siblings who should be treated with effective preventive modalities as soon as such 
treatment becomes available. 
 
The second paper set out to define characteristics that could identify individuals with a 
progressive process from among those with signs of prediabetes initially. Those with a 
progressive process were observed to be characterized by younger age, a higher number of 
detectable antibodies and higher autoantibody levels than those initially prediabetic siblings 
who remained stable or regressed. Those with a progressive process also had a reduced 
FPIR. Unfortunately, there was no single characteristic that provided complete 
discrimination between the progressing siblings and the remaining ones without any 
overlap. We found no infallible means of differentiating on an individual basis between 
those with a progressive process and those with stable or regressive β-cell autoimmunity. 
 
When observing the individual course of the prediabetic process in those siblings who 
presented with clinical T1D, one can observe that about half of the progressors did not 
change their prediabetic status at any time before diagnosis.  In the remaining half the 
pattern was highly variable, with a logical progression from no prediabetes or early 
prediabetes through advanced and late prediabetes to clinical disease in some cases but 
substantial fluctuations in others, e.g. starting from early prediabetes and passing through 
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the stages of no prediabetes, late prediabetes, advanced prediabetes and again early 
prediabetes to end up with overt T1D.  These findings suggest that the progression to 
clinical diabetes runs an individual path, and that the process is not necessarily continuously 
progressive but may regress at some point to proceed again later. Such an individual pattern 
of progression supports the “multiple hit” model, according to which an unsynchronized 
series of exogenous factors determine the path and pace of beta-cell destruction (254). The 
early identification of characteristics that differentiate between those initially antibody-
positive siblings who develop clinical T1D and those who remain unaffected turned out to 
be complicated. Although the two groups differed significantly in age and in the initial 
number of autoantibodies and their levels, there was still considerable overlap between them 
in relation to all the features analyzed. 
 
Our observations suggest that 40-60% of siblings with signs of prediabetes at the time of 
diagnosis of the index case progress further during a prospective observation period with a 
median duration of more than 3 years, while the remaining siblings retain their prediabetic 
stage or regress. Regression is common among those with early prediabetes initially, but 
rare among those with advanced or late prediabetes. Progressing siblings are characterized 
by young age, a strong humoral immune response to beta-cell antigens other than insulin 
and a reduced FPIR initially. No single characteristic is capable of distinguishing 
unequivocally between those siblings who have a progressive process and are most likely to 
develop overt T1D and those with stable or regressive beta-cell autoimmunity. 
 
 
7.4 Risk of progression to clinical type 1 diabetes in relation to autoantibodies 
and HLA-conferred disease susceptibility 
 
In general, autoantibodies alone are more sensitive for the prediction of future diabetes in 
siblings than are antibodies combined with genetic susceptibility (331). In the general 
population of Finland, the risk of developing T1D is 11-fold among subjects with the DQ 
high-risk genotype as compared with low-risk persons, and the same risk is 3.5-fold in 
siblings of affected children relative to siblings with decreased genetic susceptibility (317). 
In our third paper, late prediabetes, i.e. positivity for at least three diabetes-associated 
autoantibodies according to classification 1, gave risks as high as 775 when combined with 
HLA identity, 1809 when combined with DR3/4 heterozygosity and 1773 when combined 
with the DQB1*02/0302  genotype as compared with siblings having decreased HLA-
defined disease susceptibility and no signs of prediabetes. The combination of late 
prediabetes with genetic risk markers similarly resulted in high relative risks according to 
classification 2. Some of these risk ratios were higher than the figures of 209 associated 
with late prediabetes in classification 1, defined by autoantibodies alone, or of 1310 
conferred by the stage of late prediabetes based on classification 2, as reported in our first 
paper. These risk ratios were not significantly higher than the previous ones, however. On 
the other hand, all the siblings with a high DQ-conferred risk and late prediabetes went on 
to clinical disease, whereas less than 60% of the other siblings presented with T1D.  In the 
siblings with a reversible autoimmune process (early prediabetes), genetic susceptibility 
seems to add to the predictive power of autoantibody positivity, but when a child develops 
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autoantibodies of a more irreversible character (advanced or late prediabetes), genetic 
susceptibility adds little to the risk conferred by autoantibodies alone.  
We also observed a significantly larger proportion of siblings with late prediabetes among 
those with a strong HLA-defined disease predisposition than among those with decreased 
susceptibility, while there was a larger proportion of siblings with no signs of prediabetes 
among those with genotypes conferring decreased risk. These observations suggest that 
strong HLA-conferred disease susceptibility predisposes the individual to more advanced 
stages of prediabetes, while siblings with low risk genotypes are more likely to carry signs 
of early or no prediabetes. This indicates that HLA-conferred disease susceptibility has an 
impact on the likelihood of an autoimmune process being triggered. High-risk genotypes are 
more likely to be associated with a non-reversible immunological process, represented by 
advanced or late prediabetes.   
 
HLA-defined predisposition also seems to be predictive of progression or regression from 
the initial prediabetic stage. The stronger the genetic risk, the more likely it is that a sibling 
will progress in terms of the prediabetic stage. Inversely, the lower the genetic risk the more 
likely it is that the sibling will regress. This indicates that siblings with strong susceptibility 
genotypes not only have a higher risk of developing autoantibodies, but that their 
prediabetic autoimmune process more often represents a non-reversible process. The 
opposite was observed for siblings with HLA genotypes conferring decreased diabetes 
susceptibility, in whom the emergence of autoantibodies is infrequent, and if a prediabetic 
process is initiated it is more likely to be reversible.  
 
 
7.5 Predictive models of type 1 diabetes 
 
In the final paper we set out to design predictive models for T1D that integratw 
sociodemographic, genetic, immunological and metabolic markers and to test their utility 
for the prediction of T1D in siblings of affected children. This approach is unique in the 
sense that most earlier surveys presenting predictive models have been based on relatively 
selected populations (270; 278; 332). It is nevertheless important and clinically relevant to 
assess predictive strategies in an unselected population of siblings. According to a previous 
study, the combination of risk markers such as a multiplex family history (an additional 
sibling with T1D, or an additional parent with T1D) and genetic susceptibility conferred by 
IDDM1 (HLA) in a multivariate model allowed the identification of multiple antibody–
positive children who did not have HLA risk genotypes, including two offspring with 
protective HLA genotypes who developed multiple autoantibodies and diabetes (333). Our 
work generated a novel approach for predicting T1D with a multivariate model that 
included the HOMA-IR/FPIR ratio. The two-step predictive strategy devised in this survey 
seems to offer a feasible means of identifying those siblings of children with newly 
diagnosed diabetes who will most probably progress to clinical diabetes and for predicting 
their likely age at diagnosis. This kind of information may be useful when the parents of a 
child with recently diagnosed diabetes are to be informed about the risk of clinical disease 
in the other children within the family.  Our risk assessment is based on analysis of the HLA 
class II genotype and all four predictive autoantibody reactivities soon after T1D has been 
diagnosed in the index case. The results suggest that a short IVGTT providing fasting 
 71
glucose and insulin concentrations as well as an estimate of the early insulin response to 
intravenous glucose can provide additional data that improve the accuracy of both the risk 
and time estimates.  The HOMA-IR index also appeared to be a useful predictive marker, as 
a high value in relation to insulin secretion was observed to be associated with an increased 
risk of progression to clinical T1D. These refined predictive models may be used to identify 
individuals who would most conspicuously benefit from preventive measures aimed at 
arresting or retarding the prediabetic disease process. 
 
When considering clinical aspects of risk assessment in siblings of children with T1D, we 
must conclude from our experience that the most efficient way seems to be the screening of 
siblings close to the time of diagnosis of the index case. Based on knowledge acquired from 
this and other studies, IVGTT should be performed on all antibody-positive siblings. A 
follow-up of autoantibody-positive siblings at 6 months intervals is advisable, while 
samples taken at intervals of up to 1 year seem to be adequate for autoantibody-negative 
siblings. If a sibling remains repeatedly negative for all of the autoantibodies tested, the 
follow-up can be discontinued. 
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8 CONCLUSIONS 
 
1. The analysis of four T1D-associated autoantibodies facilitates estimation of the T1D risk 
in unaffected siblings of children with T1D. The staging of preclinical diabetes based on a 
combination of the number of antibodies and FPIR is an effective tool for grading the risk 
of T1D in family members of affected children. It is obvious, however, that it will not be 
possible to identify all siblings who will progress to clinical T1D at the time of diagnosis in 
the first affected child, since some progressors have no signs of preclinical diabetes at that 
point.  
 
2. Genetic susceptibility adds to the risk assessment based on diabetes-associated 
autoantibodies when attempting to predict progression to clinical T1D.  Increased HLA-
defined disease susceptibility is associated with a more frequent emergence of 
autoantibodies and an irreversible prediabetic process in siblings of children with T1D. In 
the siblings with a reversible autoimmune process (early prediabetes) genetic susceptibility 
seems to add to the predictive power of autoantibody positivity, but when a child develops 
autoantibodies of a more irreversible character (advanced or late prediabetes), HLA-defined 
susceptibility adds little to the risk conferred by autoantibodies alone. HLA-conferred 
susceptibility seems to have an impact on the likelihood of an autoimmune process being 
triggered. High-risk genotypes are more likely to be associated with a non-reversible 
immunological process, represented by advanced or late prediabetes. 
 
3. When looking only at siblings with late prediabetes, we observed a shorter time to 
diagnosis among those with the DQB1*0302/x genotype than among those who were 
heterozygous for DQB1*02/0302. This suggests that the DQB1*0302 allele is linked to a 
particularly aggressive autoimmune process. 
 
4. About half (40-60%) of all siblings with signs of prediabetes at the time of diagnosis of 
the index case progress further during a prospective observation period with a median 
duration of more than 3 years, while the remaining siblings retain their prediabetic stage or 
regress. Regression is common among those with early prediabetes initially, but rare among 
those with advanced or late prediabetes. Progressing siblings are characterized by young 
age, a strong humoral immune response to beta-cell antigens other than insulin and a 
reduced FPIR initially. No single characteristic, however, is capable of distinguishing 
unequivocally between those siblings who have a progressive process and are most likely to 
develop overt T1D and those with stable or regressive beta-cell autoimmunity. 
 
5. Regression of any kind was infrequent among siblings with advanced or late prediabetes 
initially, as such a phenomenon was observed in less than 10% of cases.  This finding 
emphasizes that advanced and late prediabetes do reflect destructive beta-cell autoimmunity 
that will most likely result eventually in subtotal beta-cell destruction and overt T1D, 
whereas positivity for only one autoantibody (early prediabetes) seems to represent a more 
harmless autoimmune process.   Within the time frame of the present work, close to 60% of 
the siblings with initially advanced or late prediabetes progressed to clinical T1D. These 
observations confirm previous findings indicating that a reduced FPIR often reflects 
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irreparable beta-cell damage. 
 
6. The Cox regression model devised here seemed to offer a feasible strategy for the 
identification of siblings of children with newly diagnosed diabetes who will most probably 
progress to clinical diabetes. A PRI exceeding 0.25 seems to pinpoint individuals with the 
highest risk of progression to clinical T1D, thereby functioning as an effective tool for use 
in risk assessment. This kind of information may be useful when the parents of a child with 
recently diagnosed diabetes are to be informed about the risk of clinical disease in other 
children in the family. 
 
7. The model for predicting age at diagnosis appeared to work well or satisfactorily among 
the true progressors but poorly among those who did not present with clinical T1D during 
the observation period.  
 
8. The HOMA-IR index appears to be a useful predictive marker, as a high HOMA-IR/FPIR 
ratio was observed to be associated with an increased risk of progression to clinical T1D. 
Neither the glucose elimination rate during the IVGTT nor the fasting HOMA-IR index or 
HOMA-IR/FPIR ratio had any significant impact on age at diagnosis, however. 
 
9. A short IVGTT, providing fasting glucose and insulin concentrations as well as an 
estimate of the early insulin response to intravenous glucose, can provide additional data 
that improve the accuracy of both the risk and time estimates. 
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